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INVESTIGATION OF CYP17A1 AND CYP19A1 GENE EXPRESSION 
LEVELS AND AROMATASE ACTIVITY IN INVASIVE DUCTAL BREAST 
CANCER TISSUES  
SUMMARY 
Breast cancer is the most common cancer in women worldwide, with nearly 1.7 
million new cases diagnosed in 2012. It is the second most common cancer overall. 
This represents about 12% of all new cancer cases and 25% of all cancers in women. 
The numbers of incidence and mortality is increasing especially in developing 
countries as well as in Turkey. 
Breast cancer is more commonly hormone driven and the factors that modify the risk 
of this cancer when diagnosed premenopausally and when diagnosed 
postmenopausally are not the same. Extensive research and clinical observations in 
the past 20 years confirmed that the cessation of ovarian function at menopause does 
not stop the process of sex steroid hormone synthesis in females. Currently we 
acknowledge that multiple extra-ovarian tissues contain the same enzymatic 
machinery the ovary uses which can maintain a significant rate of local hormonal 
synthesis sufficient to cause pathological outcomes. This is commonly termed 
“intracrine”.  The term intracrinology was first coined over 2 decades ago but there 
are still questions to be answered, which could help us to understand the intracrine 
mechanisms in the breast cancer microenvironment. CYP17A1 (P450c17) and 
CYP19A1 (aromatase) are two of the key enzymes in the central pathways of sex 
steroid metabolism. In current study, local expressions of CYP17A1, CYP19A1 
genes and specific activity levels of aromatase in invasive ductal breast carcinoma 
tissues were investigated by means of revealing their effect over peripheral and/or 
intratumoral estrogen production in invasive ductal breast carcinoma tissues. The 
relationship between these expressions and specific activity status along with the 
patients’ known breast health risk factors and clinicopathological parameters were 
also reported in order to investigate the effect of tumor progression. 
One tumor and one peripheral mammary adipose tissue sample (P) adjacent to the 
tumor was obtained from each patient (n= 20) and snap frozen in liquid nitrogen and 
kept at -80°C until use for the extraction of total RNA and microsome isolation. 
Real-time polymerase chain reaction was employed for the detection of CYP17A1 
and CYP19A1 gene expression. All patients were postmenopausal, diagnosed for 
invasive ductal breast carcinoma and classified as luminal A. Patients were divided 
into groups according to cilinicopathologic features and breast cancer risk factors. In 
addition, 12 tumor-free breast tissue samples (N) were obtained from premenopausal 
women with no history of breast cancer who underwent reduction mammoplasty 
surgery as the control group. The conversion of testosterone to 17ß-estradiol was 
determined via radioimmunoassay and liquid chromatography-tandem mass 
spectrometry, and the specific activity of aromatase in microsomal fractions were 
calculated. Microsomes were isolated from each specimen by employing differential 
xxi 
 
centrifugation method for the activity assays. Bicinchoninic acid protein assay was 
used for detection and quantitation of the total protein in the samples. 
The  acquired  data  pointed out the estradiol at the breast tumor microenvironment, 
which plays a major role in proliferation of malignant epithelial breast cancer cells, 
was depending on the power of local aromatization activity and the basis of this 
estrogen drive in the postmenopausal period is the adipose tissue adjacent to the 
tumor itself. The local aromatase overexpression and high aromatase activity are 
important factors for the survival of estrogen dependent breast carcinoma cells. 
Furthermore, there was a pattern consisting the combination upregulated and 
unaltered gene expressions of CYP17A1 and CYP19A1 which was observed to be 
coralated with higher aromatase activity levels in peripheral tissues compared to 
tumor tissues.  
To summarize, present study suggesting a complex breast tumor progression 
mechanism altered by CYP17A1 and CYP19A1 at the breast tumor 
microenvironment. The evaluation of various clinicopathological and disease risk 
factors along with the expression levels of CYP17A1 and CYP19A1 and the 
aromatase activity levels at breast tumor microenvironment might help clinicians to 
decide on treatment startegies and diagnosis for individual cases, particularly with 
postmenapausal status. The in-house liquid chromatography-tandem mass 
spectrometry method has the potential to be further developed to a commonly 
applied high-throughput technique for aromatase activity measurement which might 
be an invaluable asset for rapid and specific analysis. However, future studies must 
be conducted using greater sample size and addition of other key enzyme activities 
evaluations such as 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid 
dehydrogenase in streidogenesis pathway which effect local estrogen levels for 
confirmation and gettting more strong and reliable results.  
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DUKTAL MEME KANSERİ OLGULARINDA CYP17A1 VE CYP19A1 GEN 
BÖLGELERİNİN EKSPRESYONLARININ VE AROMATAZ 
AKTİVİTELERİNİN İNCELENMESİ 
ÖZET 
Meme kanseri tüm dünyada kadınlar arasında en sık görülen kanser türüdür. 2012 
yılı verilerine göre yaklaşık 1.7 milyon yeni meme kanseri tanısı konulmuştur. Genel 
olarak bakıldığında ise en sık rastlanan ikinci kanser türüdür. Bunun anlamı tüm yeni 
tanı konmuş kanserlerin %12’sini ve tüm kadınlarda görülen kanserlerin %25’ini 
meme kanseri oluşturmaktadır. Sıklık ve ölüm oranları özellikle Türkiye gibi 
gelişmekte olan ülkelerde artış göstermektedir. 
 
Meme kanseri için bazı risk faktörleri belirlenmesine karşın tanısı konulan hastaların 
çoğu için spesifik risk faktörleri tespit etmek mümkün değildir. Yüksek penetrasyon 
genleri olarak adlandırılan, özellikle BRCA1, BRCA2 ve p53 gibi, bir takım 
genlerdeki mutasyonların meme kanseri riskini çok yükselttiği bilinmektedir. Ancak, 
bu mutasyonlara çok sık rastlanmaz ve dolayısıyla mevcut vakaların az bir kısmını 
açıklamaktadır. Erken  menarş, geç  menopoz,  geç yaşta  ilk  doğum  gibi endojen 
östrojenlere uzun  süre  maruz kalma  ile  ilişkili üreme  faktörleri  meme kanseri  
için  en önemli risk faktörleri arasında yer almaktadır. Duktal epitel meme 
hücrelerindeki proliferasyonun uyarılmasının, östrojenlerin  karsinogenez  üzerindeki  
ana  etkisi  olduğu  ileri  sürülmüştür.   
 
Meme kanseri sıklıkla hormonal kaynaklı olup, bu kanseri modifiye eden risk 
faktörleri menopoz öncesi ve menopoz sonrası teşhis edildiğinde farklılıklar 
göstermektedir. Yirmi yılı aşkın süredir süren yoğun çalışmalar ve klinik gözlemler 
kadınlarda menopoz sonrası yumurtalık fonksiyonlarının kaybedilmesine rağmen 
cinsiyet steroid hormonlarının sentezlenmesinin devam ettiğini kanıtlamıştır. 
Günümüzde, yumurtalık dışı bazı dokuların yumurtalıklardakine benzer ve patolojik 
bir takım sonuçlara sebebiyet verebilecek kapasitede hormon sentezi yapabilecek bir 
enzimatik sisteme sahip olduğu bilinmektedir. Menopoz sonrası kadınlarda, 
dolaşımdaki plasma östrojen seviyelerinin düşük olduğu bilinmektedir ancak meme 
karsinogenezinde gerçekleşen lokal ve intratümoral sentez, tümör dokularında  
yüksek seviyelerde östrojen görülmesine neden olabilir. Bu durum genel anlamda 
“intrakrin etki” olarak adlandırılır. İntrakrinoloji teriminin ortaya atılmasının 
ardından yirmi yılı aşkın bir süre geçmesine karşın halen meme kanseri mikro-
çevresindeki intrakrin mekanizmaları anlamak için bize yardımcı olacak bir takım 
sorulara henüz yanıt bulunamamıştır.  
 
Östrojen biyosentezi yolağı, kolesterolden C19 androjenler ve C18 östrojenlerin 
sentezine kadar bir seri uzun enzimatik adımlardan oluşur. CYP17A1 (P450c17) ve 
CYP19A1 (aromataz) bu seks steroidlerinin metabolizmasının merkez yolağında 
bulunan iki enzimdir. P450c17 ve aromatazın katalizlediği reaksiyonlar bu yolakta 
hız sınırlayıcı basamakları oluşturduğundan özellikle önemlidirler. C21 steroidlerinin 
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P450c17 tarafından  hidroksilasyonu  ve   ardından   parçalanmasıyla   C19   
steroidleri androstenedion  ve  dehidroepiandrosteronlar  sentezlenir.  Aromataz ise 
son basamak olan  androjenlerden östrojenlerin sentezini katalizler. Mevcut 
çalışmalardan elde edilen bilgiler CYP17A1 ve CYP19A1 lokal gen ifade 
seviyelerinin potansiyel prognostik moleküler  marker  olarak  kullanılabileceğini 
düşündürmektedir. Çalışmamızda invaziv duktal meme kanseri doku örneklerindeki 
CYP17A1 ve CYP19A1 genlerinin lokal ifadesi ve aromatazın spesifik aktivitesi 
incelenmiştir. Böylelikle bu parametrelerin tümör dokusunun kendi içerisindeki 
ve/veya çevresindeki östrojen üretimini nasıl etkilediğini değerlendirmek mümkün 
olmuştur. Gen ifadesi ve aromataz aktivite seviyelerinin yanı sıra hastalara ait bilinen 
meme sağlığı risk faktörleri ve klinikopatalojik parametreler dikkate alınarak tümör 
gelişimine olan etkileri incelenmiştir. Ayrıca klinik anlamda bakıldığında, östrojen 
bağımlı meme kanseri vakalarında aromataz aktivite seviyelerini hassas, doğru ve 
hızlı bir şekilde ölçen bir yönteme ihtiyaç olduğu görülmektedir. Bu amaç 
doğrultusunda meme dokusundan spesifik aromataz aktivite ölçümlerinin 
gerçekleştirilebileceği radyoimmün test ve likit kromatografi-sıralı kütle 
spektrometresi yöntemleri geliştirilmiştir.  
 
Her bir hastaya (n= 20) ait bir tümör (T) ve bir çevre adipoz (P) meme doku örneği 
toplanmıştır. Alınır alınmaz sıvı azot ile dondurulan doku örnekleri RNA ve 
mikrozom izolasyonu yapılana kadar -80°C’de muhafaza edilmiştir. CYP17A1 ve 
CYP19A1 genlerinin dokulardaki ifade düzeyleri gerçek zamanlı polimeraz zincir 
reaksiyonu yöntemi ile incelenmiştir. Tüm hastalar menopoz sonrası durumunda 
olup, duktal invaziv meme kanseri tanısı konmuş ve sınıflandırma açısından luminal 
A tipine dahil olan vakalarıdır. Hastalar klinikopatolojik parametrelere ve taşıdıkları 
meme kanserine yakalanma risk faktörlerine göre gruplandırılmışlardır. Bunlara ek 
olarak meme küçültme ameliyatı olan ve herhangi bir kanser geçmişi olmadığı 
bilinen, menopoz öncesi durumdaki 12 hastanın rezeksiyon materyallerinden, kontrol 
grubu olarak kullanılmak üzere meme adipoz doku örnekleri (N) alınmıştır. 
Testosteronun 17ß-estradiole dönüşümü radyoimmün test ve likit kromatografi-sıralı 
kütle spektrometresi yöntemleri kullanılarak tespit edilerek mikrosomal 
fraksiyonlardaki spesifik aromataz aktivitesi hesaplanmıştır. Mikrozomal fraksiyon 
her bir örnekten diferansiyel santrifüjleme ile elde edilmiştir. Örneklerdeki toplam 
protein miktarı bikinkoninik asit protein analiz yöntemi ile tespit edilmiştir. Gruplar 
arası mRNA seviyelerindeki ve spesifik aromataz aktivitelerindeki anlamlı 
farklılıkların belirlenmesinde uygunluğuna göre Wilcoxon, Mann-Whitney U ve 
McNemar testleri gibi non-parametrik testler ile analizler gerçekleştirilmiştir.  
 
Elde edilen sonuçlar meme tümörü mikro-çevresinde gerçekleşen ve kötü huylu 
meme kanseri epitel hücrelerinin proliferasyonunda temel bir rol üstlenen estradiol 
biyosentezinin, CYP17A1 ve CYP19A1 gen ifadeleri ve lokal aromatizasyon 
aktivitesi tarafından etkilendiğini göstermektedir. Doku tiplerine göre bakıldığında 
CYP17A1 gen ifadesi seviyeleri sağlıklı bireylerdeki meme dokusunda (N) en 
yüksek olmak üzere, ardından tümörün çevresinde yer alan doku (P) ve tümör 
dokusunun kendisi (T) şeklinde sıralanmaktadır. CYP19A1 gen ifadesi seviyesi ise 
çevre dokularda diğer doku gruplarına göre oldukça yüksek bulunmuştur. Tüm 
vakalara bakıldığında, çevre dokularda tümöre göre CYP19A1’in kuvvetli bir şekilde 
upregüle olduğu (p=0.001) buna karşın CYP17A1’de ise hafif bir upregülasyon 
(p=0.687) olduğu gözlenmiştir. Bulgular menapoz sonrası dönemde estrojen 
kaynağının tümörün yakın çevresinde yer alan fibroblast ve preadipozit hücreler 
xxiv 
 
olduğu hipotezini destekler niteliktedir. Mevcut literatür bilgisi dikkate alınarak iki 
gen birlikte ifade düzeylerine göre lokal estrojen sentezini arttırıcı (IP) ve azaltıcı 
(DP) olarak gruplanarak analiz edilmiştir. CYP17A1 ve CYP19A1’in upregüle ve 
değişmemiş olduğu durumların birleşiminden oluşan arttırıcı grubun, çevre 
dokularda görülen yüksek aromataz aktivitesi ile korelasyona sahip olduğu tespit 
edilmiştir. 
 
Çevre doku ve tümör doku arasındaki gen ifade seviyelerini farkının birçok hasta 
karakteristiği tarafından etkilendiği görülmüştür.  
 
Özetle, bu çalışma meme kanseri mikroçevresindeki CYP17A1 ve CYP19A1 gen 
ifadesi değişimlerinin, karmaşık bir mekanizma üzerinden meme kanseri gelişimini 
etkilediği göstermektedir. Bahsedilen genlerin ifadesi ile birlikte meme tümörü 
mikroçevresindeki aromataz aktivitesinin çeşitli klinikopatolojik bulgular ve hastalık 
risk faktörleri de dikkate alınarak incelenmesinin, klinisyenlere kişiye göre, özelikle 
menapoz sonrası hastalarda,  teşhis ve tedavi stratejilerini belirlemede yardımcı 
olacağı düşünülmektedir. Çalışma sonucu geliştirilmiş olan likit kromatografi-sıralı 
kütle spektrometresi yöntemi hızlı ve spesifik aromataz aktivite ölçümü için rutinde 
kullanılabilecek yüksek çıktılı bir analiz olma potansiyeli yüksektir. Ancak daha 
etkin ve güvenilir sonuçlar elde etmek adına, steroidogenez yolağındaki bölgesel 
östrojen sentezini etkileyebilecek 3β-hidroksisteroid dehidrogenaz ve 17β-
hidroksisteroid dehidrogenaz gibi diğer önemli enzimlerin de aktivite değişimlerini 
değerlendirerek, daha büyük bir örneklem boyutu ile çalışmalar düzenlemek faydalı 
olacaktır. 
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 INTRODUCTION  
Every year almost two-milion women worldwide were told, “You have breast 
cancer”. Breast cancer is globally the most common form of cancer in women. 
Current statistics shows that one in eight women is at risk for developing breast 
cancer during their life time (Ferlay et al, 2015). 
The causes of breast cancer are still not fully known. For the past three decades 
breast cancer risk factors have been studied, and the single most important risk 
factor, except gender, seems to be age. Nearly half of the women, who have breast 
cancers, have no other risk factors except age and gender. The risk of breast cancer 
increases among women older than 50 years of age who have benign breast disease, 
especially those with atypical ductal or lobular hyperplasia. Both lobular and ductal 
carcinoma in situ increases risk significantly, as do a family history of breast cancer 
in first-degree relatives and the presence of BRCA1 or BRCA2 mutations. Diet, 
exercise, and environmental factors play a very small role in overall risk. On the 
other hand mammographic breast density increases relative risk fivefold among 
women with the highest density, and breast cancer risk is two to three times greater 
in women with elevated serum levels of estradiol or testosterone. Hormonally linked 
adult reproductive and anthropometric risk factors, such as young age at menarche 
(<12 years), older age at first birth (>30 years), null parity and older at the age of 
menopause (>55 years,) may contribute to the etiology of postmenopausal breast 
cancer (Vogel, 2008). 
All these can be considered as breast cancer risk increasers and have to deal with the 
fact that these women have exposed to more estrogen throughout their lives. As we 
know breast cancers are often hormonally driven and estrogen receptor positive (ER 
(+)).  About 70 - 80% of all newly diagnosed breast cancers are positive for the 
estrogen receptor and some degree positive for progesterone receptor (Hammond et 
al, 2010). All of these information points out that estrogen has a key role as a 
promoter of tumor growth. 
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The effect of estrogens in breast carcinogenesis has been investigated in cell culture, 
animal models, and humans. Breast tissue is becoming the focus point as an 
intracrine organ, with potentially important local estrogen production (Yaghjyan and 
Colditz, 2011). 
Aromatase (CYP19A1) and Cytochrome P450 17A1 (CYP17A1) are two of the key 
enzymes involved in estrogen biosynthesis (Figure 1.1).  
 
Figure 1.1: The role of CYP17A1 and CYP19A1 in estrogen biosynthesis pathway. 
Enhancement of aromatase expression and activity have been shown in various 
cancers, including breast tumors, hepatocellular carcinoma, adrenocortical tumors 
and testicular tumors (Bulun and Simpson, 2008; Jongen et al, 2006; Carruba, 2009; 
Bulun et al, 1997; Young et al, 1996; Aiginger et al, 1981). Particularly in the case of 
breast cancer, it is strongly possible that local paracrine and/or intracrine estrogen 
signaling is stimulating the progression and recurrence of the disease, especially in 
hormone receptor positive carcinomas. Paracrine interactions between malignant 
breast epithelial cells, proximal adipose fibroblasts, and vascular endothelial cells are 
responsible for estrogen biosynthesis and the lack of adipogenic differentiation in 
breast cancer tissue. It is most likely malignant epithelial cells secrete factors that 
inhibit the differentiation of surrounding adipose fibroblasts for their maturation and 
3 
 
stimulate aromatase expression in these undifferentiated adipose fibroblasts (Meng et 
al, 2001). The in vivo presence of malignant epithelial cells also enhances aromatase 
expression in endothelial cells in breast tissue (Zhou et al, 2001). After ovarian 
function subsides during menopause or after another pathological change or medical 
intervention that reduces or eliminates ovarian function, peripheral estrogen 
synthesis by aromatase becomes the primary pathway for the production of estrogen 
in women. In addition to Aromatase, CYP17A1 activity, which is at a critical 
crossroad point in the pathways of steroid hormone biosynthesis, also has been 
demonstrated in breast cancer tissues more than three decades ago (Abul-Hajj et al, 
1979). The relation between breast cancer and CYP17A1 have been considerably 
evaluated but findings are mixed and no firm conclusions can be drawn at present 
(Feigelson et al, 1997; Helzlsouer et al, 1998; Setiawan et al; 2007; Chen et al, 
2008). Although studies suggest a possibility that CYP17A1 may be involved in in 
situ synthesis of estrogens, and the overexpressions of CYP17A1 messenger 
ribonucleicacid (mRNA) might affect intratumoral estrogen levels as well. 
 Breast Cancer by Numbers in The World and Turkey 
Breast cancer, with an estimated number of 1.67 million new cases in 2012, is by far 
the most common cancer diagnosed in women worldwide (ranking second when both 
sexes combined). It means that nearly a quarter of all cancers diagnosed in women is 
breast cancer (25%) (Ferlay et al, 2015). In most countries worldwide, incidence of 
breast cancer has increased in the last decades, with the most rapid increases 
occurring in developing countries underlying  causes are thought to be the 
differences in  reproductive behavior, the use of exogenous hormones, as well as 
differences in weight, exercise, diet and alcohol consumption among these countries 
(Beral and Million Women Study Collaborators, 2003; Reeves et al, 2007; 
Monninkhof et al, 2007; Allen et al, 2009).  
Across the regions of the world, female breast cancer incidence rates vary nearly 
five-fold. The highest incidence rates in 2012 belong to Belgium and Denmark 
(111.9 and 105  age standardized rate per 100000, respectively). Figure 1.2 is 
showing the 2012 estimates of the incidence rates in Western Asia region which 
Turkey is included. The average incidence rate is 42.8 per 100000. With the number 
of 39.1, Turkey is in 13th place across the region (Ferlay et al, 2015). 
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The most common cause of death from cancer in women worldwide is also breast 
cancer (ranking fifth when both sexes combined). It’s estimated to be responsible for 
almost 522,000 deaths in 2012. Its nearly one third of the newly diagnosed cases. 
Variation in female breast cancer mortality across the regions of the world is less, 
largely due to better survival in the (high incidence) developed countries. 
According to GLOBOCAN 2012 data, the average mortality rate of Western Asia 
region is 15.1 per 100000. Turkey is in 11th place across the region with 13.4 per 
100000 (Ferlay et al, 2015).  
 
Figure 1.2: Breast cancer, females, Western Asia age-standardised incidence and 
mortality rates, 2012 estimates. 
According to data of the Department of Cancer Control, incidence rate for Turkish 
women was 38.6 per 100000 in 2010 (Figure 1.3) (Köse et al, 2014). 
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Figure 1.3: Incidence of the most common four types of cancer in women in Turkey, 
2008-2010 (per 100.000, World standard population). 
If we look at the future prospects, World Health Organization (WHO) estimates are 
suggesting 64% and 49% increase in incidence and mortality numbers in Turkey 
between 2015 and 2035 (Figure 1.4). 
 
Figure 1.4: Estimated number of new breast cancer cases and mortality in Turkey. 
Although in the last decade, incidence rate and prevalance have increased three times 
in Turkey, there is not a nationwide screening program yet. There are big differences 
regarding stage at diagnosis, and effective treatments between eastern and western 
part of Turkey which is largely due to late presentation of the disease, limited 
resources for diagnosis and treatment, lack of breast health awareness, social, 
cultural, and educational factors. The most fundamental interventions are early 
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detection, diagnosis, surgery, radiation therapy, and drug therapy can be integrated 
and organized within existing health care schemes in Turkey and other low and 
middle income countries (Özmen et al, 2009). 
 Classification of Breast Cancer 
Breast cancer is a cancer that starts in the breast, usually in the inner lining of ducts 
or lobules. Although the definition seems to be simple, classification of the disease 
can be complex. Breast cancers can be classified according to different aspects. Each 
of these can influence treatment response and prognosis. Description of a breast 
cancer would optimally include all of these classification aspects, as well as other 
findings, such as signs found on physical exam. A full classification includes 
histopathological type, grade, stage (TNM), receptor status, and the presence or 
absence of genes as determined by genetic testing. 
1.2.1 Histopathologic classification 
According to the World Health Organization (WHO), there are more than 100 types 
and subtypes of breast tumors. Simplified version of this classification is shown in 
Table 1.1 (Lakhani et al, 2012). 
Table 1.1: Simplified classification of tumors of the breast. 
Epithelial tumours Others 
Invasive ductal carcinoma Lobular neoplasia Myoepithelial lesions 
Invasive lobular carcinoma Intraductal proliferative lesions Mesenchymal lesions 
Tubular Microinvasive ca Fibroepithelial tumours 
Invasive cribriform Intraductal papillary neoplasms Tumours of the nipple 
Medullary Benign epithelial proliferations Malignant lymphoma 
Mucinous ca and other tumours 
with abundant mucin Adenomas Metastatic tumours 
Neuroendocrine tumors Oncocytic ca Tumours of the male breast 
Invasive micropapillary ca Adenoid cystic ca  
Apocrine ca Acinic cell ca  
Metaplastic carcinomas Glycogen-rich clear cell ca  
Lipid-rich ca Sebaceous ca  
Secretory ca Inflammatory ca  
Oncocytic ca Invasive papillary ca  
Adenoid cystic ca   
Acinic cell ca   
 
Ductal carcinomas are members of epithelial tumors in this classification. Invasive 
ductal carcinoma (IDC), which is our study group belongs, is the most common type 
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of breast cancer. It refers that cancer cells has broken through the wall of the milk 
duct and begun to invade the tissues of the breast (Figure 1.5). 
 
Figure 1.5: Invasive ductal breast cancer and the progression model. 
1.2.2 Grading 
The Nottingham (also called Elston-Ellis) modification of the Scarff-Bloom-
Richardson grading system, is recommended, which grades breast carcinomas by 
adding up scores for tubule formation, nuclear pleomorphism, and mitotic count, 
each of which is given 1 to 3 points (Elston and Ellis, 2002; Bloom and Richardson, 
1957; Genestie et al, 1998). The scores for each of these three criteria and then added 
together to give an overall final score and corresponding grade as follows: 
• 3-5 Grade 1 tumor (well-differentiated). Best prognosis. 
• 6-7 Grade 2 tumor (moderately-differentiated). Medium prognosis. 
• 8-9 Grade 3 tumor (poorly-differentiated). Worst prognosis. 
Lower grade tumors, with a more favorable prognosis, can be treated less 
aggressively, and have a better survival rate. Higher grade tumors are treated more 
aggressively, and their intrinsically worse survival rate may warrant the adverse 
effects of more aggressive medications.  
1.2.3 Staging 
The TNM classification for staging breast cancer is based on the size of the cancer 
where it originally started in the body and the locations to which it has moved. These 
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cancer characteristics are described as the size of the tumor (T), whether or not the 
tumor has spread to the lymph nodes (N) in the armpits, neck, and inside the chest, 
and whether the tumor has metastasized (M) (Table 1.2) (Edge et al 2010). Larger 
size, nodal spread, and metastasis have a larger stage number and a worse prognosis. 
Stage 0 which is in situ disease or Paget's disease of the nipple. Stage 0 is a pre-
cancerous or marker condition, either ductal carcinoma insitu (DCIS) or lobular 
carcinoma insitu (LCIS). Stages I–III are within the breast or regional lymph nodes. 
Stage IV is a metastatic cancer. Metastatic breast cancer has a less favorable 
prognosis. 
Table 1.2: Anatomic stage/prognostic groups. 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB 
T0 N1mi M0 
T1* N1mi M0 
Stage IIA 
T0 N1 M0 
T1 N1 M0 
T2 N0 M0 
Stage IIB 
T2 N1 M0 
T3 N0 M0 
Stage IIIA 
T0 N2 M0 
T1* N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
Stage IIIB 
T4 N0 M0 
T4 N1 M0 
T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
1.2.4 Molecular Subtype 
The receptor status of breast cancers has traditionally been identified by 
immunohistochemistry (IHC), which stains the cells based on the presence of 
Estrogen Receptors (ER), Progestin Receptors (PR) and Human Epidermal Growth 
Factor Receptor 2 (HER2). This remains the commonest method of testing for 
receptor status, but deoxyribonucleic acid (DNA) multi-gene expression profiles can 
categorize breast cancers into molecular subtypes that generally correspond to IHC 
receptor status (Table 1.3). 
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Table 1.3: Molecular subtypes of breast tumors (Yang et al; 2011). 
Subtype These tumors tend to be 
Luminal A ER (+) and/or PR (+), HER2-, low Ki67 
Luminal B 
 
ER (+) and/or PR (+), HER2 (+) (or HER2 (-) with high Ki67) 
 
Triple negative/basal-like ER (-), PR (-), HER2 (-), cytokeratin 5/6 (+) and/or HER1 (+)  
HER2 (+) ER (-), PR (-), HER2 (+) 
Receptor status is a critical assessment for all breast cancers as it determines the 
suitability of using targeted treatments such as tamoxifen and or trastuzumab. These 
treatments are now some of the most effective adjuvant treatments of breast cancer. 
ER+ cancer cells depend on estrogen for their growth, so they can be treated with 
drugs to reduce either the effect of estrogen (e.g. tamoxifen) or the actual level of 
estrogen (e.g. aromatase inhibitors), and generally have a better prognosis. Generally, 
prior to modern treatments, HER2 (+) had a worse prognosis (Sotirou and Pusztai, 
2009), however HER2 (+) cancer cells respond to drugs such as the monoclonal 
antibody, trastuzumab, (in combination with conventional chemotherapy) and this 
has improved the prognosis significantly (Romond et al., 2005). Conversely, triple 
negative cancer (i.e. no positive receptors), lacking targeted treatments now has a 
comparatively poor prognosis (Dent et al, 2007).  
Androgen receptor is expressed in 80-90% of ER (+) breast cancers and 40% of 
"triple negative" breast cancers. Activation of androgen receptors appears to suppress 
breast cancer growth in ER (+) cancer while in ER (-) breast it appears to act as 
growth promoter. Efforts are underway to utilize this as prognostic marker and 
treatment (Lehmann et al, 2011; Hu et al, 2011).  
Receptor status was traditionally considered by reviewing each individual receptor 
(ER, PR, HER2) in turn, but newer approaches look at these together, along with the 
tumor grade, to categorize breast cancer into several conceptual molecular classes  
that have different prognoses and may have different responses to specific therapies 
(Prat and Perou, 2011; Geyer et al, 2009). 
1.2.5 Other classification approaches 
Understanding the specific details of a particular breast cancer may include looking 
at the cancer cell DNA by several different laboratory approaches. When specific 
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DNA mutations or gene expression profiles are identified in the cancer cells this may 
guide the selection of treatments, either by targeting these changes, or by predicting 
from the DNA profile which non-targeted therapies are most effective. 
 Estrogens and Breast Cancer 
The growth of female breast depends upon several hormones, the most important of 
which is estrogen. Estrogen governs the development of the ductal system of the 
breast whereas progesterone is responsible for the proper development of the lobular 
system. 
There are three major estrogens naturally synthesized in women; estrone (E1), 
estradiol (E2), and estriol (E3). The predominant estrogen during reproductive years 
both in terms of absolute serum levels as well as in terms of estrogenic activity is E2. 
The biologically active estrogen E2 is produced in at least three major sites: 1) direct 
secretion from the ovary in reproductive-age women; 2) by conversion of circulating 
androstenedione (A) of adrenal and/or ovarian origins to E1 in peripheral tissues; and 
3) by conversion of A to E1 in estrogen-target tissues (Figure 1.6). During 
menopause, estrone is the predominant circulating estrogen and during pregnancy 
estriol is the predominant circulating estrogen in terms of serum levels. Though 
estriol is the most plentiful of the three estrogens it is also the weakest, whereas 
estradiol is the strongest. Thus, estradiol is the most important estrogen in non-
pregnant females who are between the menarche and menopause stages of life.  All 
of the different forms of estrogen are synthesized from androgens, specifically 
testosterone and androstenedione, by the enzyme aromatase. 
As mentioned in introduction section, lifetime exposure to estrogens correlates with 
the incidence of breast cancer in women at risk (Santen, 2007). In the hormone-
dependent subtype of breast cancers, the role of estrogens as modulators of 
mitogenesis overrides the influence of other factors. These sex steroids stimulate cell  
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Figure 1.6: Main sources of estrogens in women. 
proliferation directly by increasing the rate of transcription of early response genes 
such as c-myc and indirectly through stimulation of growth factors which are 
produced largely in response to estrogenic regulation. Enhanced cell proliferation, 
induced either by endogenous or by exogenous estrogens,  increases the  number of 
cell divisions and, by inference, the proportionate number of mutations. With an 
enhanced rate of proliferation, the time available for DNA repair is reduced. In 
addition, occurrence of single-stranded DNA, during cell cycle, is more susceptible 
to damage than double-stranded DNA (Figure 1.7). This is the predominant theory at 
the present time relates to effects of estrogen on cell growth. Another current theory 
is that estrogens can be metabolized to genotoxic products. These two current 
theories of enhanced cell proliferation and genotoxic metabolites are not mutually 
exclusive but could act in an additive or even synergistic fashion. For example, DNA 
damage originating from catechol estrogens would be propagated more rapidly by 
increased cellular proliferation, and insufficient time might be available for DNA 
repair (Jefcoate et al, 2000). 
The risk of breast cancer and exposure to estrogen have a close relation so it is 
important to examine the key variables in estrogen homeostasis (i.e., the synthesis 
and catabolism of estrogen and the sensitivity of tissue to estrogen). The initial entry 
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Figure 1.7: Diagrammatic representation of the two pathways whereby estrogens can 
cause breast cancer.  
of cytosolic cholesterol into the mitochondrion, which is facilitated by steroidogenic 
acute regulatory protein (StAR), represents a major step for steroidogenesis. Six 
enzymes encoded by at least five specific genes then catalyze the conversion of 
cholesterol to the biologically active estrogen estradiol. Both CYP17A1 (encoding 
P450c17) and CYP19A1 (encoding aromatase) are involved in estrogen biosynthesis. 
In situ aromatization in breast tumors results in increased estrogen in breast tissue, 
which may contribute to the growth of breast tumors in an autocrine or paracrine 
manner. Suppression of tissue-specific inhibitors of the promoter may also result in 
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increased synthesis of aromatase mRNA. Thus, the aromatase gene may act as an 
oncogene that initiates tumor formation in breast tissue (Clemons and Goss, 2001). 
 CYP17A1 and CYP19A1 
1.4.1 CYP17A1 and P450c17 
The CYP17A1 gene is present in the genomes of all Chordata species and encodes an 
evolutionarily conserved P450 protein. The human gene spans approximately 10 kb 
on chromosome 10q24.3, encompassing eight exons separated by seven introns 
(Picardo-Leonard and Miller, 1987) (Figure 1.8). The human mRNA appears to be 
ubiquitously expressed in all tissues, with the highest levels detected in testis and 
adrenals. Transcription is initiated approximately 180-bp upstream of the initiation 
codon in exon 1 and produces ~1.7 kb mRNA and it encodes a 508 amino acid 
enzyme (P450c17, EC 1.14.99.9). This enzyme is a membrane-bound dual-function 
monooxygenase with a critical crossroad point in the pathways of human steroid 
hormone biosynthesis, catalyzing two different enzymatic reactions, the 17α-
hydroxylation and 17,20-lyase reactions of the C21-steroids. 17α-hydroxylase 
activity is required for generation of glucocorticoids like cortisol, while its 
hydroxylase and 17,20-lyase activities are required for production of androgenic and 
estrogenic sex steroids (Voutilainen and Miller, 1986). P450c17 determines the final 
products in steroid hormone biosynthesis and plays an important role in cell 
homeostasis. Thus, when the 17α-hydroxylase activity of P450c17 predominates, the 
biosynthesis of steroid hormones is directed mainly to the biosynthesis of 
glucocorticoids. If the 17,20-lyase activity of P450c17 is predominant, then 
biosynthesis of steroid hormones is directed to the production of sex hormones 
(Martucci and Fishman, 1993).  
There are several CYP17A1 polymorphism studies, which are related to breast 
cancer risk (Kaufman et al, 2011; Wang et al, 2009; Tüzüner et al, 2010). However, 
there are currently no studies directly investigates the relationship between local gene 
expressions levels of CYP17A1 gene and breast cancer susceptibility. 
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Figure 1.8: Schematic representation of the human CYP17A1 gene. 
CYP17A1 is a target for inhibiting the growth of hormone-dependent cancers 
including breast cancer. Abiraterone, which is a potent and selective CYP17A1 
inhibitor, has been proposed as a viable treatment option in women with metastatic 
ER (+) breast cancer as well as with triple-negative disease that are AR (+). There 
are still further studies required to better characterize which breast cancer patients 
may benefit the most (Capper et al, 2016).  
1.4.2 CYP19A1 and aromatase 
Aromatase is encoded by a single copy of the CYP19A1 gene located on the short 
arm of chromosome 15 (15q21.2) (Figure 1.9) (Harada et al, 1990). It is 
approximately 120 kb long and comprises 10 exons. Nine coding exons (II-X) span 
approximately 30kb, and there are a number of alternative non-coding first exons 
which are expressed in a tissue- specific manner. As various tissues utilize their own 
promoters and associated enhancers and suppressors, the tissue-specific regulation of 
estrogen synthesis is very complex. Although the transcripts for aromatase have 
different 5’ ends in various tissues depending on the promoter usage, these unique 
first exons are spliced into a common 3’-junction upstream of the start of translation, 
resulting in the synthesis of identical aromatase proteins (Sebastian and Bulun, 
2001).  
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Figure 1.9: Structure of the human CYP19A1 gene. Expression of the aromatase  
gene is regulated by the tissue-specific activation of a number of promoters via 
alternative splicing. 
The most proximal gonadspecific promoter II and two other proximal promoters, I.3 
(expressed in adipose tissue and breast cancer) and I.6 (expressed in bone) are found 
to be located within the 1 kb region upstream of the ATG translation start site in 
exon II. Promoter I.2, the minor placenta-specific promoter, is located approximately 
13 kb upstream of the ATG site in exon II. The promoters specific for the brain (I.f ), 
endothelial cells (I.7), fetal tissues (I.5), adipose tissue (I.4) and placenta (2a and I.1) 
are localized in tandem order at ~ 3, 36, 43, 73, 78 and 93 kb, respectively, upstream 
of the first coding exon, the exon II (Figure 1.9). In addition to promoter II specific 
sequences, transcripts containing two other unique sequences, untranslated exons I.3 
and I.4, are present in adipose tissue and in adipose tissue fibroblasts maintained in 
culture. Transcription initiated by use of each promoter gives rise to a transcript with 
a unique 5’-untranslated end that contains the sequence encoded in the first exon 
immediately downstream of this particular promoter (Figure 1.9). Therefore, the 5’-
untranslated region of aromatase mRNA is promoter specific and may be viewed as a 
signature of the particular promoter used. It should be emphasized again that all of 
these 5’-ends are spliced onto a common junction 38 bp upstream of the ATG 
translation start site. Thus, use of alternative promoters does not affect protein 
structure but its expression level. 
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1.4.2.1 Aromatase enzyme 
Human aromatase is a 58 kDa protein that was purified from placental microsomes in 
the late 1980s (Mendelson et al, 1987). The protein is highly conserved among all 
vertebrates. Aromatase enzyme complex is comprised of two polypeptides. The first 
of these is aromatase cytochrome P450 (P450arom) which is a specific cytochrome 
P450 and the product of the CYP19A1 gene. The second is a flavoprotein, 
nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P450 reductase 
and is ubiquitously distributed in most cells. Thus, cell-specific expression of 
P450arom determines the presence or absence of aromatase activity. Since only a 
single gene (CYP19A1) encodes aromatase in humans, targeted disruption of this 
gene or inhibition of its product effectively eliminates estrogen biosynthesis 
(Simpson et al, 2002). 
The functional human enzyme is comprised of a heme group and a polypeptide chain 
of 503 amino acid residues. It is an integral membrane protein of the endoplasmic 
reticulum, anchored to the membrane by an amino (N)-terminal transmembrane 
domain (Figure 1.10-A) (Sohl and Guengerich, 2010; Sebastian and Bulun, 2001). 
Aromatase has been the topic of intense biochemical and biophysical investigations 
for the past 50 years because of its unique hydroxylation reaction that involves a 
carbon-carbon bond cleavage and a ring aromatization in the estrogen biosynthesis 
pathway (Santen et al, 2009; Simpson et al, 2005; Ryan,1959). 
Aromatase is the final enzyme in the central pathways of sex steroid metabolism and 
is probably the best characterised enzyme in intratumoral steroid production in breast 
cancer. Aromatase irreversibly commits steroids to an estrogenic lineage through 
aromatisation of the A ring of the steroid backbone in a sequential, three-step 
reaction (Figure 1.10-C). Aromatase can act on either androstenedione or 
testosterone (TES), forming either the relatively weaker estrogen–E1, or the more 
potent estrogen–E2. This formation, first identified in 1959 (Ryan, 1959), requires 
three molecules each of NADPH and O2 and proceeds through two relatively stable 
intermediates, the 19-hydroxy and 19-aldehyde compounds, before the final 
aromatization step. There has been considerable debate over the chemistry of the 
third step, and two mechanisms are currently favored. The model proposes that the 
ferric peroxide form of the P450 (FeOO-, Figure 1.10-B) attacks the aldehyde, 
followed by heterolytic cleavage of the peroxide bond and the transfer of the 1β 
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proton of the steroid to the heme to generate a ferrous hydroxy intermediate, with the 
loss of formic acid (Akthar et al, 1982; Cole and Robinson, 1991). 
    
Figure 1.10: The aromatase enzyme complex and conversion of androgens to 
estrogens. A) Computer-assisted docking model of the aromatase-reductase complex. 
A ribbon representation of the reductase (green) - aromatase (blue) complex showing 
its association with endoplasmic reticulum membrane (purple).  B) General P450 
catalytic cycle. C) The three steps of the A ring aromatization.  
It’s known that aromatase is expressed by different cell types such as granulosa cells, 
Leydig and Sertoli cells, placental cells, neurons, preadipocytes and fibroblasts, 
vasculature smooth muscle cells, chondrocytes, and osteoblasts (Simpson et al, 
1994). Therefore, estrogens are not only produced in gonads but also brain, adipose 
tissue, breast, skin, blood vessels, bone, and cartilage (Simpson, 2003). Expression 
levels show interpersonal and regional differences, and they are different at various 
stages of life, e.g. fetal liver expresses aromatase, but it is not present in adult liver 
(Simpson et al, 2002). 
1.4.2.2 Aromatase and breast cancer 
The desmoplastic reaction (Figure 1.11) is essential for structural and biochemical 
support for tumor growth. The “scirrhous cancer” term was used by pathologists for 
most of the invasive ductal carcinoma cases, indicating the rock-like consistency of 
these tumors (Haagensen, 1986). Accumulation of fibroblasts around malignant 
epithelial cells serves to maintain the strikingly hard consistency in many of these 
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tumors and increased local concentrations of estrogen via aromatase overexpression 
localized to these undifferentiated fibroblasts. 
 
Figure 1.11: The desmoplastic tissue reaction in breast cancer.  
Extraordinarily large quantities of tissue necrosis factor (TNF) and interleukin-11 
(IL-11) are produced and secreted by malignant breast epithelial cells (Meng et al, 
2001). Therefore, large numbers of these estrogen-producing cells are maintained 
adjacent to malignant cells. At the same time, a separate set of factors secreted by 
malignant epithelial cells activates aromatase expression in surrounding adipose 
fibroblasts (Meng et al, 2001). This tumor-induced block in adipocyte differentiation 
is mediated by the selective inhibition of expression of the essential adipogenic 
transcription factors, namely, CCAAT/enhancer-binding protein alpha (C/EBPα) and 
peroxisome proliferator-activated receptor gamma (PPAR-γ) (Figure 1.12). The 
inhibition of differentiation of fibroblasts to mature adipocytes mediated by TNF and 
IL-11 is the key event responsible for desmoplastic reaction. Moreover, blocking 
both TNF and IL-11 in cancer cell conditioned medium using neutralizing antibodies 
is sufficient to reverse this antidifferentiative effect of cancer cells completely. 
(Meng et al, 2001).   
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Figure 1.12: Detail of epithelial-stromal interaction via estrogen and cytokines in 
breast cancer. 
The pathologic significance of local aromatase activity in breast cancer was also 
supported via in vitro studies. MCF7 breast cancer cells, which were stably 
transfected to express an mouse mammary tumor virus- promoter-driven human 
aromatase complementary DNA (cDNA) and inoculated into oophorectomized nude 
mice, remained dependent on circulating androstenedione for their rapid growth (Yue 
et al., 1994). Further evidence for the importance of local aromatase expression in 
the breast tissue came from an in vivo mouse model demonstrating that aromatase 
overexpression in breast tissue is sufficient for maintaining hyperplasia in the 
absence of circulating estrogen and that aromatase inhibitors abrogated hyperplasia 
(Tekmal et al., 1999). These transgenic mice with mouse mammary tumor virus 
promoter-driven local aromatase in breast tissue are more prone for breast cancer 
development (Kovacic et al., 2004).  
 The Scope of Current Study 
In this study, local expressions of CYP17A1, CYP19A1 genes and activity levels of 
aromatase in invasive ductal breast carcinoma tissues were investigated by means of 
revealing their effect over peripheral and/or intratumoral estrogen production in 
invasive ductal breast carcinoma tissues. For this purpose, tumor and neighboring 
mammary adipose tissues from which is diagnosed pathologically  as invasive ductal 
breast cancer were collected. CYP17A1, CYP19A1 expressions and aromatase 
activity were compared within the groups while healthy breast tissue group was used 
as control. Two different methods, a radiaimmunoassay (RIA) and a liquid 
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chromatography-tandem mass spectrometry (LC-MS/MS) based, were developed for 
the measurement of the aromatase activity. The results were evaluated further in 
view of the clinicopathological characteristics and breast cancer risk factors. When 
taken together, the present results revealed significant clues on possible mechanism 
of the estrogen dependent breast cancer initiation and progression in postmenapausal 
women, which is promising for estrogen driven risk estimations and patient specific 
treatment decision making in clinical practice. 
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 MATERIAL AND METHODS 
 Materials 
2.1.1 Patient selection and tissue samples 
Tumor (T) and neighboring adipose tissues (P) were obtained from 20 female 
patients who did not receive adjuvant chemotherapy before surgery and underwent 
mastectomy or breast conserving surgery due to invasive ductal breast cancer at the 
department of Surgery, Cerrahpasa Faculty of Medicine in Istanbul University during 
the period of January 2010 – December 2012. Surgically resected tissues were 
subjected to pathological examination to diagnose and confirm the correct sampling 
of tumor and adipose tissue at department of Pathology, Cerrahpasa Faculty of 
Medicine in Istanbul University. One tumor and one neighboring mammary adipose 
tissue sample was obtained from each patient. They were snap frozen in liquid 
nitrogen and kept at -80°C until use for the determination of aromatase activity and 
for the extraction of total RNA. All patients were classified as luminal A (ER(+), PR 
(+), HER2 (-)) and postmenapausal. Only tumor cells with distinct nuclear 
immunostaining for ER and PR were recorded as positive. The ER and PR status of 
the patients were defined by immunohistochemistry on formalin-fixed, paraffin-
embedded sections of clinical specimens as part of routine pathological 
interpretation. Immunohistochemistry was performed using a rabbit monoclonal 
antihuman ER antibody (clone SP1; Thermo-Scientific, MA, USA) and a polyclonal 
rabbit antihuman PR antibody (clone 16, Novocastra, Leica Microsystem, Wetzlar, 
Germany). Two different pathologists evaluated ER/PR immunohistochemical 
stainings. Nuclear staining of > 10% of cells were accepted as positive for ER or PR 
status. According to chromogen intensity, dark and intense staining of receptors was 
evaluated as strong intensity; otherwise, it was accepted as weak intensity. In 
addition 12 tumor-free breast tissue samples (N) were obtained from premenopausal 
women with no history of breast cancer (age range= 20-40 years) who underwent 
reduction mammoplasty surgery as the control group. None of them had any kind of 
cancer history (before surgery, breast ultrasonography was performed and after 
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surgery, specimens of these patients were all clean as pathologically) and any known 
metabolic disease. They attented to surgery outpatient clinic with thoracic, upper 
back and neck/shoulder pain or severe intertriginous dermatitis and cosmetic 
problems. Informed written consent about the study was obtained from each patient. 
2.1.2 Chemicals 
Chemicals used in this study are listed in Table 2.1. 
Table 2.1: Chemicals. 
Chemical Producer 
Dipotassium phosphate Merck Millipore 
Potassium dihydrogen phosphate Merck Millipore 
Sodium cholate Applichem 
Tween 20 Promega 
Phenylmethylsulfonyl fluoride (PMSF)  Applichem 
NADPH regenerating system (A-B)  BD Biosciences 
Trichloroacetic acid   Sigma-Aldrich 
Acetonitrile HPLC grade Panreac 
Trietilamine Pierce 
Ortophosphoric acid   Merck Millipore 
Ethanol Merck Millipore 
Chloroform Merck Millipore 
Glycerol Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Applichem 
DMSO Calbiochem 
Phosphate buffered saline (PBS) Medicago 
Estradiol Sigma Aldrich 
Testosterone Sigma Aldrich 
Estrone Sigma Aldrich 
17-β Estradiol Radioimmunoassay kit MP Biomedicals 
Methanol HPLC grade Merck 
Water HPLC grade Merck 
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Table 2.1 (Continued): Chemicals. 
Chemical Producer 
Trizol Reagent Ambion 
Purelink RNA Mini kit Ambion 
RNase away Invitrogen 
High Capacity RNA-to-cDNA Kit Applied Biosystems 
TaqMan® Gene Expression Assays Applied Biosystems 
Bicinchoninic acid (BCA) Protein assay Pierce 
 
2.1.3 Buffers and solutions  
Buffers and solutions that were used in this study are listed in Table 2.2. 
 Buffers and solutions. 
Buffer/Solution Concentration 
PBS (pH: 7,4)  Working solution: 1X 
Potassium phosphate buffer (pH: 7,4) 0,5 M 
EDTA 2 mM 
Sodium cholate 10 mM 
PMSF 200 mM 
Glycerol 20 % (v/v) 
Tween 20 0,2 % (v/v) 
Tricloroacetic acid 0,1 % (w/v) 
Testosterone 5 mM 
 
2.1.4 Laboratory equipments 
Laboratory equipments that were used in this study are listed in Table 2.3. 
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 Laboratory equipments. 
Laboratory Equipment Producer 
Autoclave TOMY SX-700E High Pressure Steam Sterilizer 
Deep freezers and refrigerators 
 
-80 ̊C Sanyo Ultra Low Freezer 
-20 ̊C Arçelik 
+4 ̊C Arçelik 
Spectrophotometer  NanoDrop ND-1000 
Microplate spectrophotometer Thermo Multiskan SPECTRUM 
Agilent 1200 High performance liquid 
chromatography (HPLC) system Agilent Technologies 
HPLC Column  Agilent Technologies 
Agilent 6460 Jet-Stream Triple Quad Mass 
Spectrometry (MS) System Agilent Technologies 
Solid Phase Extraction (SPE) Columns Waters 
Vacuum manifold Agilent Technologies 
Vacuum pump Rocker Scientific Tanker 150 
Incubator Memmert UM 400 
Microfuge Nüve NF 048 
Ultracentrifuge Beckman Coulter ProteomeLab™ XL-A 
Micropipettes Thermo Scientific 
pH meter Mettler Toledo MP 220 
Mortar and pestle Haldenwanger 
Homogenizer Analytik Jena SpeedMill PLUS 
Beads Next Advance Zirconium 0,5mm 
Real time PCR system ABI 7500 
Ultrapure water system  Millipore Milli-Q Plus PF 
Ultracentrifuge Beckman Coulter ProteomeLab™ XL-A 
Micropipettes Thermo Scientific 
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Table 2.3 (Continued): Laboratory equipments. 
Laboratory Equipment Producer 
Water bath Memmert WNB 10 
Ultrasonic bath Ultrasonic LC 30 
Gamma counter Packard Cobra 5000 Series B5003 
Heating block Biosan CH-100 
Vortex LMS VTX-3000L 
Analytical balance Libror AEX-200G 
Heated magnetic stirrer Heidolph MR 3001 
 Methods 
Overview of current study’s workflow can be summarized as in Figure 2.1. 
 
Figure 2.1: Workflow of the methods which were used in present study.  
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2.2.1 Total RNA isolation from tumor and neighbouring adipose tissues 
Approximately 100-150 mg of tissue was grinded with liquid nitrogen using a 
ceramic mortar and pestle. TRIzol® reagent (Ambion) was used in conjunction with 
the PureLink® RNA Mini Kit (Ambion) to isolate total RNA from samples. A 
modification was made in manufacturer’s protocol. We added an extra centrifugation 
step before choloroform addition in order to avoid excess fat content of the samples, 
which effects the RNA yields and interferes qRT-PCR. (Figure 2.2.). Determination 
of RNA concentrations following RNA isolation was done by using NanoDrop 1000 
Spectrophotometer (Thermo Scientific). 
 
Figure 2.2: Modified RNA isolation method. 
2.2.2 Analysis of expression levels of CYP17A1 and CYP19A1 by qRT-PCR  
cDNA synthesis from isolated total RNA was performed according to High Capacity 
RNA-to-cDNA Kit protocol (Applied Biosystems). The sequences of primers and 
probes were shown in Table 2.4. Total RNA concentration was adjusted to 500 
ng/reaction. qRT-PCR analysis was performed according to protocol of TaqMan® 
Gene Expression Assay (Applied Biosystems) kit by using Applied Biosystems® 
7500 Real-Time PCR. Primer and probe sequences used in qRT-PCR analysis were 
shown in Table 2.4. 
Carboxyfluorescein (FAM) reporter dye and minor groove binder (MGB) were 
attached at the 5' and 3' end of each probe, respectively. Briefly, 20 µl total PCR 
reaction contained; 1 µl of 20✕ TaqMan® Gene Expression Assay, cDNA, 10 µl of 
2✕ TaqMan® Gene Expression Master Mix, 4 µl of cDNA template and 2 µl 
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RNase-free water. PCR reaction was conducted as follows: 50°C (2 min) for Uracil 
N-glycosylase (UNG) incubation, 95°C (10 min) for polymerase activation and then 
40 cycles at 95°C (15 sec) / 60°C (1 min). TATA binding box protein (TBP) gene 
was used as the internal control group. The gene expression levels analysed ΔΔCt 
method (Livak and Schmittgen, 2001). 
Table 2.4: Primer and probe sequences used in qRT-PCR analysis  
 CYP17A1 CYP19A1 
Forward 5'-TCACAATGAGA AGGAGTGGCAC -3' 
5′-TGTGGACGTG 
TTGACCCTTCT-3′ 
Reverse 5'-TACTGACGGTG AGATGAGCTGG -3' 
5′-ACCACGATAG 
CACTTTCGTCCA-3′ 
Probe 5'- TGCCTGAGCGTT TCTTGAATCCAGC-3' 
5′-ATGCTGGACACCTCT 
AACACGCTCTTCTTGA-3′ 
2.2.3 Isolation of microsomes by differential centrifugation 
Weighed tissues were pulverized with liquid nitrogen using a ceramic mortar and 
pestle and transferred to 1,5 mL microcentrifuge tubes containing 0.5mm diameter 
zirconium beads (Next Advance) and homogenization buffer (1x PBS (pH 7.4), 20% 
gliserol, 1 mmol/L EDTA). 1 mL of homogenization buffer was used for each 100mg 
of tissue sample. PMSF (0,2 mmol/L) was added just before homogenization. 
Homogenization was performed with SpeedMill Plus (Analytik Jena). The 
microsomal fraction was prepared with 105,000 g pellet which obtained from 9,000 g 
supernatant of the homogenate. The pellet obtained was resuspended in solubilization 
buffer (1x PBS (pH 7.4), 20% gliserol, 1 mmol/L EDTA, 1mmol/L sodium cholate 
and 0,2% Tween 20) and allowed to stand at 4°C overnight.  
2.2.4 Bicinchoninic acid (BCA) protein assay 
The Thermo Scientific Pierce BCA Protein Assay was used for the colorimetric 
detection and quantitation of total protein in patient samples. Assay was conducted 
according to manufacturer’s instructions. Bovine serum albumine (BSA) was used  
as standart. 25µL of each standard or patient sample replicate was pipetted into a 
microplate well (working range = 20-2000µg/mL). 200µL of the working reagent 
was added to each well and plate was mixed thoroughly on a plate shaker for 30 
seconds. Plate was covered and incubated at 37°C for 30 minutes and cooled to room 
temperature. Absorbance was measured at 562nm on the plate reader (Thermo 
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Multiskan SPECTRUM). the average 562nm absorbance measurement of the blank 
standard replicates were subtracted from the 562nm measurements of all other 
individual standard and patient sample replicates. A standard curve was prepared by 
plotting the average blank-corrected 562nm measurement for each BSA standard vs. 
its concentration in µg/mL. The standard curve was used to determine the protein 
concentration of each sample. 
2.2.5 Aromatase activity assay 
Aromatase activity assay was performed as described previously (Zharikova et al., 
2006). Briefly, the activity of microsomal fractions in catalyzing the conversion of 
testosterone to 17-ß estradiol (E2) was determined in a total reaction volume of 1 mL 
potassium phosphate buffer (0,5M pH 7.4). Testosterone (total reaction concentration 
0,5 µg/mL) were added to the reaction solution and preincubated for 5 min at 37C. 
The reaction was initiated by the addition of NADPH regenerating system (NADP 
0.4 mM, glucose-6-phosphate (G-6-P) 4 mM, G-6-P dehydrogenase 1 U/mL, and 2 
mM MgCl2) and incubated for 5 min at the same temperature. The reaction was 
terminated by the addition of 100 µL of a 10% (w/v) trichloroacetic acid and placed 
on ice. Estrone (E1), 0,5 µL of  100µg/mL solution, was spiked to each tube as an 
internal standard. In addition a blank sample was prepared with same materials and 
conditions but without substrate.  
2.2.6 Solid phase extraction (SPE) of the samples 
The solid phase extraction protocol (Newman et al., 2008) was used with slight 
modifications, for extraction of 17-ß estradiol formed after aromatase activity assay. 
Briefly, protocol involves six major steps: (1) Solvation, columns were primed with 
ethanol; (2) Equilibration, water was passed through columns to prepare sorbent for 
sample loading; (3) Sample loading, samples in aqueous matrix were passed through 
the columns; (4) Interference elution, water was passed through columns to wash out 
interfering polar substances; (5) Sample elution, estradiol was eluted from columns 
with a small amount of eluant into 7 mL glass tubes; (6) Drying & storing, eluates 
were dried and stored at – 20°C (Figure 2.3).  
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Figure 2.3:  SPE procedure applied to the samples. 
For SPE, a 20-place vacuum manifold (Vac Elut 20, Agilent Technologies), 
endcapped C18 columns (Sep-Pak C18 Plus Short Cartridge, 360 mg sorbent, 55-105 
µm particle size, Waters), and 10 mL disposable syringes without needles were used 
(Figure 2.4).  
Sample	drying	&	storing:	Dry	eulates under	N2 at	40°C	then	store	at	-20°C.
Divide	eulates into	two	(one	for	LC-MS/MS,	one	for	RIA)	and	dry	&	store	separetly.	
Use	vacuum	to	prompt	MeOH to	flow,	then	turn	off	vacuum	and	wait	for	all	MeOH to	drip	
slowly	through	columns,	then	turn	on	the	vacuum	for	2	min	to	collect	remaining	MeOH.
Sample	elution:	add	1	mL	90%	MeOH (HPLC	grade)	to	syringes,	soak	for	2	min		(twice).
After	second	elution,	apply	vacuum	for	5	min	to	remove	excess	dH2O.	Then	insert	clean	
glass	tubes	into	vacuum	manifold.
Interference	Elution:	Add	5	mL	dH2O	to	syringes	(twice)
Apply	vacuum	to	allow	samples	to	flow	through	columns	until	0,1	mL	remains.
Sample		loading:	Add	~1	mL	of	sample	to	syringes
Apply	vacuum	to	allow	dH2O	to	flow	through	columns	until	0,1	mL	remains.
Equilibration:	Add	5	mL	dH2O	to	syringes	(twice)
Apply	vacuum	to	allow	EtOH to	flow	through	columns	until	0,1	mL	remains.
Solvation:	Add	3	mL	HPLC	grade	EtOH to	syringes	&	soak	for	2	min
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Figure 2.4: SPE set up for the extraction of samples after activity experiment. 
2.2.7 Measurement of  E2 formation 
E2 formation was measured for the calculation of specific aromatase activity in the 
samples. Measurements were performed with two different methods: RIA and LC-
MS/MS. 
2.2.7.1 Measurement via RIA 
For detection of E2 formed in samples,  ImmuChem Double Antibody 125I RIA kit  
for 17ß-Estradiol (MP Biomedicals) was used. This kit was desinged for in vitro 
diagnostic use in serum or plasma samples. Kit’s protocol was followed but only 
sample preperation procedure of the kit was modified for aromatase activity assay 
samples. Evaporated extracts of aromatase assay samples were resuspended  and 
dilluted 100 fold  with standart 1 (0 pg/mL). Then 50 µL of  it  used for each  related 
tube. 100, 1000 and 2500 pg/mL E2 were prepared with standart 1 and used as 
controls. All standarts, controls  and unknown samples were studied double. E2 
measurements were performed with a gamma counter (Packard Cobra 5000 Series-
B5003) at Istanbul University School of Medicine, Endocrinology Department.  
2.2.7.2 Measurement via LC-MS/MS 
Standart and sample preparation  
Working standards of E1, E2 and TES were prepared by diluting 1 mg/mL stock 
solutions in methanol. Calibrators containing E1, E2 and TES in concentrations of 1, 
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10, 100, 250, 500 and 1000 ppb were prepared in the same matrix. Perivously 
evaporated and stored samples dissolved in 100 µL methanol before injection.  
LC-MS/MS conditions  
LC–MS/MS analysis was carried out on a Agilent 6460 Jet-Stream Triple Quad 
System with Agilent 1200 Series HPLC system. A C18 reversed-phase column 
(3.0×30mm; 1.8µm, Zorbax SB-C18) with an online filter was used for 
chromatographic separation. HPLC conditions are shown in Table 2.5 and MS/MS 
instrument parameters are shown in Table 2.6. The data were collected and 
quantified using Agilent Mass Hunter software. 
Table 2.5: HPLC conditions. 
Time (min) Solvent A (%) 
(Mobile Phase A) 
Solvent B (%)                   
(Mobile Phase B)  
Flow (ml/min) 
0 100 0 0.6 
2.60 90 10 0.6 
2.70 60 40 0.6 
4.00 60 40 0.6 
Solvent A ACN + 0.1% (v/v) formic acid  
Solvent B H2O + 0.1% (v/v) formic acid 
Column temprature 40 °C 
Autosampler Set a 2 sec needle wash, using the flushport 
Injection volume 1µL 
Table 2.6: MS/MS conditions. 
Ion source ESI (Agilent Jet Stream) 
Polarity Positive 
Gas Temperature 350 °C 
Gas Flow 13 L/min 
Nebulizer Pressure 40 psi 
Sheath Gas Temperature 400 °C 
Sheath Gas Flow 12 L/min 
Capillary Voltage 6000 V (positive) 
Nozzle Voltage 2000 V (positive) 
Resolution MS1 and MS2 Wide resolution 
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2.2.8 Statistical analysis 
We conducted our analysis among three groups (P: Peripheral, T: Tumor, N: 
Healthy), which were grouped according to the tissue type. We especially focused 
our analysis on peripheral tissue group due to the hypothesis that it is the source of 
aromatase activity in breast cancer tissue microenvironment. All calculations were 
performed using SPSS Statistical Program Version 21.0 (SPSS Inc. Chicago, USA).  
The significance of differences in mRNA levels and aromatase activities were 
determined by the Wilcoxon Signed Ranks (WSR) test, Manwhitney U (MU) test or 
McNemar (MN) test as needed. Moreover, kappa values (κ) were obtained and 
results were interpreted according to the study previously reported (Landis and Koch 
1977). Briefly κ ranges generally from 0 to 1.0 (although negative numbers are 
possible) where large numbers meaning better reliability, values near or less than 0 
suggest that the agreement is attributable to chance alone. All reported p-values are 
from two-sided tests and a value less than 0.05 was considered statistically 
significant. 
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 RESULTS 
 Clinical Characteristics of Selected Patients 
The mean age (± SD) of the study group (n=20) was 59.65± 11.94 years. Most 
patients had disease of histological grade II or higher (17/20, 85.0%) and stage of the 
disease is IIa or worse (15/20, 75.0%) The primary characteristics of the study 
population are given in Table 3.1. 
Table 3.1: Clinicopathological characteristics of patients (n=20). 
Patient characteristics Mean±SD Range 
Age (years) 59.65 ±11.94 46 - 87 
BMI (kg/m2) 27.871 ±5.06 22.3 - 37.0 
 Status n (%) 
Histological grade I 3 (15.0%) 
II 12 (60.0%) 
III 5 (25.0%) 
Stage 
Ia 5 (25.0%) 
IIa 7 (35.0%) 
IIIa 2 (10.0%) 
IIIc 4 (20.0%) 
IV 2 (10.0%) 
Lymphatic vascular invasion Yes 10 (50.0%) No 10 (50.0%) 
Axilla invasion Yes 7 (35.0%) No 13 (65.0%) 
Insitu component Yes 18 (90.0%) No 2 (10.0%) 
Blood vessel invasion Yes 0 (0.0%) No 20 (100.0%) 
Necrosis  Yes 6 (30.0%) No 14 (70.0%) 
Perineural invasion Yes 13 (65.0%) No 7 (35.0%) 
Calcification  Yes  7 (35.0%) No  13 (65.0%) 
Ki67 Yes 14 (70.0%) No 6 (30.0%) 
 Breast Cancer Risk Factors  
The study group was homogeneous according to receptor status and disease type 
which all patients were ER (+) PR (+) and diagnosed as invasive ductal carcinoma. 
Half of the group have lymphatic vascular invasion. None of the patients had blood 
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vessel invasion and more than half (65.0%, 70.0% and 65.0%) were lack of axilla 
invasion, necrosis and calcification, respectively. However, presence of  an in situ 
component,  perineural invasion and Ki67 were detected in most of the cases. 
According to indicated risk factors, more than half of the patients bearing the “low 
risk” conditions, except body mass index (BMI), oral contraceptive use and age at 
menopause (Table 3.2).  
Table 3.2: Breast cancer risk factor distribution among the study group. 
 
Risk factors 
Patients (n = 20) 
High risk Low risk 
Body mass index (BMI-kg/m2) 
≥ 25 < 25 
11 (55%) 9 (45%) 
Family history of cancer 
Yes No 
5 (25%) 13 (65%) 
History of cancer in breast 
Yes No 
4 (20%) 16 (80%) 
First-degree relatives with breast cancer 
Yes No 
3 (15%) 15 (75%) 
Age at first full-term pregnancy 
≥ 30 < 30 
4 (20%) 12 (60%) 
Smoking 
Yes No 
8 (40%) 12 (60%) 
Alcohol intake 
Yes No 
6 (30%) 14 (70%) 
Age at menarche 
< 12 ≥ 12 
4 (20%) 16 (80%) 
Parity 
Nulliparous Multiparous 
4 (20%) 16 (80%) 
Breast feeding 
No Yes 
- 16 (80%) 
Age at menopause 
≥ 45 < 45 
17 (85%) 3 (15%) 
Oral contraceptive use 
Yes No 
2 (10%) 18 (90%) 
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 CYP17A1 and CYP19A1 Expressions 
qRT-PCR analysis was performed according to protocol of TaqMan® Gene 
Expression Assay (Applied Biosystems) kit by using Applied Biosystems® 7500 
Real-Time PCR. The gene expression levels calculated according to the 2-(ΔΔCt) 
method are shown in Table 3.3.  
Table 3.3: The expression levels of CYP17A1 and CYP19A1 genes normalized with 
TATA Binding Box Protein (TBP) housekeeping gene, as determined by qRT- PCR. 
Sample 
name 
CYP17A1-TBP 
∆Ct Mean 
∆∆Ct 2-(∆∆Ct) 
CYP19A1-TBP 
∆Ct Mean 
∆∆Ct 2-(∆∆Ct) 
N 10.60 0.00 1.00 14.87 0.00 1.00 
P01 10.63 0.02 0.98 11.99 -2.89 7.39 
P02 11.20 0.60 0.66 17.28 2.41 0.19 
P03 10.22 -0.38 1.70 16.13 1.26 0.42 
P04 6.97 -3.64 12.43 11.52 -3.35 10.23 
P05 9.99 -0.62 1.53 13.99 -0.88 1.84 
P06 8.88 -1.72 3.30 11.62 -3.25 9.54 
P07 13.38 2.77 0.15 11.58 -3.30 9.82 
P08 10.55 -0.05 1.04 14.49 -0.38 1.30 
P09 9.10 -1.50 2.84 10.93 -3.94 15.37 
P10 10.21 -0.39 1.31 14.86 -0.01 1.01 
P11 9.26 -1.34 2.54 13.93 -0.94 1.92 
P12 11.40 0.80 0.58 15.74 0.87 0.55 
P13 14.00 3.40 0.09 14.21 -0.66 1.58 
P14 5.82 -4.78 27.55 10.02 -4.85 28.89 
P15 12.28 1.68 0.31 10.74 -4.13 17.54 
P16 13.04 2.44 0.185 12.13 -2.74 6.69 
P17 12.87 2.27 0.21 18.65 3.78 0.07 
P18 15.06 4.46 0.05 13.68 -1.19 2.29 
P19 12.61 2.01 0.25 13.47 -1.40 2.64 
P20 11.56 0.96 0.52 15.29 0.42 0.75 
T01 10.30 -0.30 1.23 17.04 2.17 0.22 
T02 15.07 4.47 0.05 18.49 3.62 0.08 
T03 8.97 -1.63 3.10 19.79 4.92 0.03 
T04 7.55 -3.05 8.31 13.03 -1.84 3.59 
T05 7.26 -3.34 10.15 16.21 1.34 0.40 
T06 10.49 -0.11 1.08 15.70 0.83 0.56 
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Table 3.3 (Continued): The expression levels of CYP17A1 and CYP19A1 genes 
normalized with TATA Binding Box Protein (TBP) housekeeping gene, as 
determined by qRT- PCR. 
Sample 
name 
CYP17A1-TBP 
∆Ct Mean 
∆∆Ct 2-(∆∆Ct) 
CYP19A1-TBP 
∆Ct Mean 
∆∆Ct 2-(∆∆Ct) 
T07 11.72 1.12 0.46 12.21 -2.66 6.33 
T08 13.59 2.99 0.13 14.79 -0.08 1.06 
T09 7.75 -2.85 7.23 11.44 -3.43 10.80 
T10 18.50 7.90 0.004 16.20 1.33 0.40 
T11 14.46 3.86 0.07 15.07 0.20 0.87 
T12 15.17 4.57 0.04 20.24 5.37 0.02 
T13 11.78 1.18 0.44 13.04 -1.83 3.56 
T14 5.98 -4.62 24.66 11.46 -3.41 10.65 
T15 7.06 -3.54 11.66 13.18 -1.69 3.23 
T16 13.11 2.51 0.176 14.74 -0.13 1.10 
T17 12.97 2.37 0.19 20.14 5.27 0.03 
T18 12.02 1.42 0.37 18.53 3.66 0.21 
T19 11.77 1.17 0.45 16.14 1.27 0.86 
T20 12.70 2.10 0.23 16.18 1.31 0.98 
 
According to tissue types, CYP17A1 expression levels were ordered as N>P>T. 
CYP19A1 was highly expressed in P compared to both other types. Among all cases, 
there was a strong upregulation of CYP19A1 and a slight upregulation of CYP17A1 
in peripheral tissue compared to paired tumor tissues (Figure 3.1).  
 
Figure 3.1: Overall expressions of CYP17A1 and CYP19A1 in tissue groups 
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Nearly 3 fold higher CYP19A1 expression levels were observed in peripheral tissues 
compared to tumor tissues (Z= -3.397, p=0.001 [WSR]). However the upregulation 
of CYP17A1 was unable to reach statistical significance (Z= -0.402, p=0.687 
[WSR]) (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Box plots of relative qRT-PCR gene expression measurements of 
CYP17A1 and CYP19A1 in peripheral and tumor breast tissues. The dotted lines 
represent the cut-off value which is 1,5 for gene expression fold changes. 
The relative expression levels of CYP17A1 and CYP19A1 of individual patients are 
shown in Figure 3.3. Healthy tissue sample expression levels were used as controls.  
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
 
 
 
 
 
 
 
 
Figure 1. (A) CYP17A1 and CYP19A1 gene expression plots by tissue type.  (B)Distribution of peritumoral and 
tumor tissue CYP17A1 expression levels (1.5 cut off) among the patients and fold change difference (* WSR 
test, 2-tailed, not significant). (C) Distribution of peritumoral and tumor tissue CYP19A1 expression levels (1.5 
cut off) among the patients and fold change difference (* WSR test, 2-tailed, significant). Normal breast tissue 
expression levels used as controls in calculations. 
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p=0.001
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p=0.687
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Figure 1. (A) CYP17A1 and CYP19A1 gene expression plots by tissue type.  (B)Distribution of peritumoral and 
tumor tissue CYP17A1 expression levels (1.5 cut off) among the patients and fold change difference (* WSR 
test, 2-tailed, not significant). (C) Distribution of peritumoral and tumor tissue CYP19A1 expression levels (1.5 
cut off) among the patients and fold change difference (* WSR test, 2-tailed, significant). Normal breast tissue 
expression levels used as controls in calculations. 
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p=0.687
*'
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Figure 3.3: The fold change of CYP17A1 and CYP19A1 gene in peripheral and 
tumor tissue of each patient. Results shown as fold change (log 2 relative 
quantification (RQ)). The healthy tissue group was used as reference. 
Table 3.4 and Table 3.5 summarize the significant associations of patient 
characteristics with CYP17A1 and CYP19A1 expression levels in peripheral tissue 
compared to healthy and tumor tissue, respectively.  
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Table 3.4: Tissue CYP17A1 expression levels for the patient characteristics. P vs. N: 
Peripheral tissue compared to healthy breast tissue, P vs. T: Peripheral tissue 
compared to tumor tissue, PR: Progesterone receptor. (*) All patients have positive 
PR staining status, with different intensity. Nuclear staining of  > 10% of cells were 
accepted as positive for ER or PR status. 
 
 
Patient characteristic 
P vs N P vs T 
Up 
regulated 
n (%) 
Down regulated / 
No alteration 
n (%) 
Up 
regulated 
n (%) 
Down regulated / 
No alteration 
n (%) 
Histological 
grade 
I 1 (33.3) 2 (66.7) 1 (33.3) 2 (66.7) 
II+III 5 (29.4) 12 (70.6) 7 (41.2) 10 (58.2) 
p-Value  (kappa) 0.003 (-0.016) 0.012 (0.035) 
Stage 
I 1 (20.0) 4 (80.0) 1 (20.0) 4 (80.0) 
Others 5 (33.3) 10 (66.7) 7 (46.7) 8 (53.3) 
p-Value  (kappa) 0.012 (0.083) 0.039 (0.182) 
In situ 
component 
Yes 6 (33.3) 12 (66.7) 8 (44.4) 10 (55.6) 
No - 2 (100.0) - 2 (100.0) 
p-Value  (kappa) 0.0005 (0.091) 0.002 (0.138) 
PR status* 
Weak intensity - 5 (100.0) 1 (20.0) 4 (80.0) 
Strong intensity 6 (40.0) 9 (60.0) 7 (46.7) 8 (53.3) 
p-Value  (kappa) 0.004 (0.250) 0.039 (0.182) 
 
Age 
≥ 50 4 (28.6) 10 (71.4) 5 (35.7) 9 (64.3) 
< 50 2 (33.3) 4 (66.7) 
3 (50.0) 3 (50.0) 
p-Value  (kappa) 0.039 (-0.034) 0.146 (-0.111) 
Parity 
Nulliparous 2 (50.0) 2 (50.0) 1 (25.0) 3 (75.0) 
Multiparous 4 (25.0) 12 (75.0) 7 (43.8) 9 (56.2) 
p-Value  (kappa) 0.013 (-0.129) 0.021 (0.107) 
Age at 
menopause 
≥ 45 5 (29.4) 12 (70.6) 8 (47.1) 9 (52.9) 
< 45 1 (33.3) 2 (66.7) - 3 (100.0) 
p-Value  (kappa) 0.003 (-0.016) 0.004 (0.212) 
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Table 3.5: Tissue CYP19A1 expression levels for the patient characteristics. P vs. N: 
Peripheral tissue compared to healthy breast tissue, P vs. T: Peripheral tissue 
compared to tumor tissue. 
 
Patient characteristic 
P vs N P vs T 
Up 
regulated 
n (%) 
Down regulated / 
No alteration 
n (%) 
Up 
regulated 
n (%) 
Down regulated / 
No alteration 
n (%) 
Axilla 
invasion 
Yes 5 (71.4) 2 (28.6) 7 (100.0) - 
No 8 (61.5) 5 (38.5) 7 (53.8) 6 (46.2) 
p-Value  (kappa) 0.109 (0.083) 0.016 (0.375) 
Family 
history of 
cancer 
Yes 4 (80.0) 1 (20.0) 4 (80.0) 1 (20.0) 
No 8 (61.5) 5 (38.5) 8 (61.5) 5 (38.5) 
p-Value  (kappa) 0.039 (0.129) 0.039 (0.129) 
History of 
cancer  
Yes - 4 (100.0) 2 (50.0) 2 (50.0) 
No 13 (81.3) 3 (18.7) 12 (75.0) 4 (25.0) 
p-Value  (kappa) 0.049 (-0.441) 0.013 (-0.129) 
Age at first 
full-term 
pregnancy 
≥ 30 3 (75.0) 1 (25.0) 3 (75.0) 1 (25.0) 
< 30 8 (66.7) 4 (33.3) 7 (58.3) 5 (41.7) 
p-Value  (kappa) 0.039 (0.053) 0.070 (0.111) 
Age at 
menarche 
< 12 - 4 (100.0) 1 (25.0) 3 (75.0) 
≥ 12 13 (81.3) 3 (18.7) 13 (81.3) 3 (18.7) 
p-Value  (kappa) 0.049 (-0.441) 0.021 (-0.290) 
Oral 
contraceptive 
use 
Yes 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 
No 12 (66.7) 6 (33.3) 13 (72.2) 5 (27.8) 
p-Value  (kappa) 0.003 (-0.048) 0.002 (-0.061) 
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We created two groups according to the common findings in literature  (O’Neill et 
al., 1988; Bulun et al., 1993; Harada et al., 1993; Reed et al., 1993; Sasano et al., 
1994; Utsumi et al., 1996; Zhou et al., 1996; Miyoshi et al., 2003) of how these 
CYPs’ mRNAs act over local estrogen production in breast, estrogen increasing (IP) 
and estrogen decreasing (DP) pattern, by combining both CYPs’ expression status 
(Table 3.6).  The significant associations of DP and IP conditions with patient 
characteristics are analayzed and shown in Table 3.7. 
Table 3.6: Distribution of CYP17A1 and CYP19A1 expression status together by 
threshold value (≥1.5-fold change) for different tissue comparison groups. P vs. N: 
Peripheral tissue compared to healthy breast tissue, P vs. T: Peripheral tissue 
compared to tumor tissue. 
Group 
mRNA alteration 
(CYP17A1/CYP19A1) 
P vs. N 
(n= 20) 
P vs. T 
(n= 20) 
Local Estrogen Increasing 
Expressional Pattern (IP) 
up/up 6 (30.0%) 5 (25.0%) 
up/unaltered 1 (5.0%) 4 (20.0%) 
Unaltered/up - 2 (10.0%) 
Local Estrogen Decreasing 
Expressional Pattern (DP) 
up/down 6 (30.0%) 5 (25.0%) 
Unaltered/down 1 (5.0%) 1 (5.0%) 
Down/down 3 (15.0%) 2 (10.0%) 
Down/up - 1 (5.0%) 
Down/unaltered 1 (5.0%) - 
Unaltered/unaltered  2 (10.0%) - 
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Table 3.7: The combined effect of CYP17A1 and CYP19A1 expression 
levels for different subgroups of patient characteristics. DP: Local estrogen 
production decreasing expressional pattern, IP: Local estrogen production 
increasing expressional pattern, P vs. N: Peripheral tissue compared to healthy 
breast tissue, P vs. T: Peripheral tissue compared to tumor tissue, PR: 
Progesterone receptor. (*) All patients have positive PR staining status, with 
different intensity. Nuclear staining of > 10% of cells were accepted as 
positive for ER or PR status. 
 
 
 P vs N P vs T 
Patient characteristic DP n (%) 
IP 
n (%) 
DP 
n (%) 
IP 
n (%) 
Histological grade 
I 1 (33.3) 2 (66.7) 1 (33.3) 2 (66.7) 
II+III 6 (35.3) 11 (64.7) 10 (58.8) 7 (41.2) 
p-Value  (kappa) 0.006 (0.008) 0.070 (0.140) 
Stage 
I 1 (20.0) 4 (80.0) 1 (20.0) 4 (80.0) 
Others 6 (40.0) 9 (60.0) 10 (66.7) 5 (33.3) 
p-Value  (kappa) 0.021 (0.130) 0.216 (0.368) 
In situ component 
Yes 7 (38.9) 11 (66.1) 11 (66.1) 7 (38.9) 
No - 2 (100.0) - 2 (100.0) 
p-Value  (kappa) 0.001 (0.113) 0.016 (0.239) 
PR status* 
Weak intensity 1 (20.0) 4 (80.0) 3 (60.0) 2 (40.0) 
Strong intensity 6 (40.0) 9 (60.0) 8 (53.3) 7 (46.6) 
p-Value  (kappa) 0.021 (0.130) 0.344 (-0.053) 
Parity 
Nulliparous 2 (50.0) 2 (50.0) 8 (50.0) 8 (50.0) 
Multiparous 5 (31.2) 11 (68.8) 3 (75.0) 1 (25.0) 
p-Value  (kappa) 0.022 (-0.102) 0.227 (-0.170) 
Age at menopause 
≥ 45 6 (35.3) 11 (64.7) 1 (33.3) 2 (66.7) 
< 45 1 (33.3) 2 (66.7) 10 (58.8) 7 (41.2) 
p-Value  (kappa) 0.006 (0.008) 0.070 (0.140) 
Oral contraceptive use 
No  - 2 (100.0) 10 (55.6) 8 (44.4) 
Yes 7 (38.9) 11 (66.1) 1 (50.0) 1 (50.0) 
p-Value  (kappa) 0.180 (-0.180) 0.012 (-0.019) 
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There was no statistically significant association between factors such as BMI, 
smoking, alcohol consumption, lymphovascular invasion, perineural invasion, 
necrosis, calcification, Ki67 and expressional differences neither as individual nor 
combined (DP and IP) in P, T or N group. 
3.4 Protein Concentrations 
Protein measurement analysis was performed according to the Pierce BCA Protein 
Assay (Thermo Scientific) protocol by using the Multiskan Spectrum plate reader 
(Thermo Scientific). Figure 3.4 shows the calibration graph, while Table 3.8 shows 
sample protein concentrations calculated via this graph.  
 
Figure 3.4: BCA protein assay calibration graph. 
 
 
 
 
 
 
 
y = 807,62x - 12,433
R² = 0,99931
0
200
400
600
800
1000
1200
1400
1600
0 0,5 1 1,5 2
pr
ot
ei
n 
(µ
g/
m
L
)
Absorbance (562nm)
44 
 
 
Table 3.8: Protein concentrations of the samples. 
Sample name Protein (µg/mL) Sample name Protein (µg/mL) 
N 112,99 T01 250,55 
P01 39,73 T02 231,16 
P02 16,99 T03 136,44 
P03 86,64 T04 137,11 
P04 109,95 T05 75,46 
P05 2,74 T06 156,64 
P06 59,84 T07 247,16 
P07 42,30 T08 377,87 
P08 6,87 T09 257,86 
P09 183,00 T10 425,48 
P10 215,74 T11 337,76 
P11 94,03 T12 215,44 
P12 9,00 T13 170,06 
P13 78,80 T14 181,05 
P14 28,27 T15 58,88 
P15 126,82 T16 311,45 
P16 168,29 T17 989,12 
P17 156,09 T18 809,74 
P18 39,09 T19 401,68 
P19 186,78 T20 333,84 
P20 442,65   
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3.5 Aromatase Activity  
3.5.1. RIA measurements 
RIA measurements were conducted as previously described in Methods section. The 
calibration graph for standarts between 10-3000 pg/mL is shown in Figure 3.5.  
 
Figure 3.5: Calibration curve for the RIA measurements of E2. 
In order to eliminate the matrix effect, measured E2 concentrations of patient samples 
(P and T) were normalized via substracting the measurement of the blank sample. 
Afterwards specific activity of aromatase (U.mg-1) was calculated. Overall, we 
observed higher activity both in P and T than N, where the levels in T were slightly 
higher than N (Figure 3.6). The activity levels for each sample are shown in Figure 
3.8. The highest specific aromatase activity was 3336,58.10-5 U.mg-1 and observed in 
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the peripheral tissue. The lowest specific aromatase activity was 17,24.10-5 U.mg-1 
and observed in the tumor tissue (Figure 3.7).  	
 
Figure 3.6: Relative aromatase activity levels for tumor and peripheral tissue 
samples among patients. The activity of healthy tissue samples which is 
represented here as the dotted line were used as reference. Calculations were 
made according to RIA measurements. 
  
 
Figure 3.7: Specific activity of aromatase for tumor and peripheral tissue 
samples among patients. Calculations were made according to RIA 
measurements. (*) Activity of P for patient 5# was 3336,58.10-5 U.mg-1; (**) 
activity of P for patient 8# was 1302,67.10-5 U.mg-1. 
* ** 
x10-5	
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More than half of the patients were observed to have higher activity in peripheral 
breast tissue compared to tumor tissue and the difference was statistically significant 
(Z= -3.51, p= 0.0004 [WSR]) (Figure 3.8-A). 70% of the measured aromatase 
activities were found to be consistent with CYP19A1 expression level results (Figure 
3.8-B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: The distribution of aromatase activity levels calculated in regards 
of RIA measurements among the patients: A) P activity levels compared to T 
activity levels, the difference less than 2 fold was accepted as not changed; B) 
Crossmatched results of activity and expression levels for P compared to T. 
Low: Low aromatase activity, High: High aromatase activity, Down: 
CYP19A1 downregulated, Up: CYP19A1 upregulated. 
 
A 
B 
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When the expression levels of CYP17A1 and CYP19A1 were taken into 
consideration  together, the fold difference of aromatase activity between P and T 
was higher in IP group (Figure 3.9). However the difference did not reach statistical 
significance. (p= 0.569 [MU]) 
 
Figure 3.9: P/T aromatase activity levels calculated via RIA measurements 
among the estradiol decreasing (DP) and increasing (IP) expression pattern 
bearing groups. Upper outliers were not shown. 
The significant associations of patient characteristics with specific aromatase 
activity, measured via RIA, in peripheral tissue compared to tumor tissue are 
summarized at Table 3.9. Oral contraceptive usage, presence of necrosis and absence 
of calcification were found associated with high activity levels in peripheral tissue, 
where other known factors were not. 
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Table 3.9: Tissue aromatase activitiy levels measured via RIA for different 
subgroups of patient characteristics. P < T: Peripheral tissue activity lower than 
tumor tissue activity, P > T: Peripheral tissue activity greater than tumor tissue 
activity. 
3.5.2. LC-MS/MS measurements 
In parallel to RIA measurement, we measured E2 concentration of the same samples 
via LC-MS/MS.  
Quantitative analysis was carried out using multiple reaction monitoring (MRM) 
mode and MRM transitions are shown in Table 3.10. Two MRM transitions per 
analyte were monitored (quantifier and qualifier) and a ratio of their peak areas was 
used for analyte confirmation.  All of the samples were scanned for the quantifier, 
qualifier ions for each target analyte and MRM mass spectrums were obtained 
(Figure 3.10). 
The calibration curves for the target compounds between 1-1000 ppb are shown in 
Figure 3.11. All calibration curves were generated using linear fit, no inclusion of the 
origin. All curves had linearity coefficients of at least 0.99 and showed good 
reproducibility and accuracy at the lowest levels. LOD and LOQ values for E2 and 
TES were shown in Table 3.11. 
 
 
Patient characteristics P < T 
n (%) 
P > T 
n (%) 
Oral contraceptive use Yes 0 (0.00) 2 (100.00) 
No 4 (22.20) 14 (78.80) 
p-Value  (kappa) 0.00012 (0.054) 
Necrosis Yes 1 (16.70) 5 (83.30) 
No 3 (21.40) 11 (78.60) 
p-Value  (kappa) 0.006 (0.032) 
Calcification Yes 2 (28.60) 5 (71.40) 
No 2 (15.40) 11 (84.60) 
p-Value  (kappa) 0.022 (-0.102) 
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Table 3.10: Mass Transitions of testosterone (TES) and estradiol (E2). 
 Compound Percursor ion 
MS1 
Res 
Product 
ion 
MS2 
Res 
Dwell 
time 
(ms) 
Fragmentor 
Voltage (V) 
Collision 
Energy 
(V) 
Polarity 
Qualifier TES 289.1 Wide 108.9 Wide 25 110 20 (+) 
E2 255.1 Wide 133 Wide 100 90 14 (+) 
Quantifier 
TES 289.1 Wide 96.9 Wide 25 110 18 (+) 
E2 255.1 Wide 158.9 Wide 100 90 12 (+) 
 
 
 
Figure 3.10: MRM mass spectrums of the quantifier and qualifier ions for 
each target analyte. 
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Figure 3.11: LC-MS/MS calibration curves of E2 and TES. 
 
Table 3.11: LOD,LOQ and accuracy values for E2 and  TES 
 LOD (ppb) LOQ (ppb) Accuracy (Mean, ±SD) 
Estradiol 9,29 28,16 100,91 ± 14,06 
Testosterone 14,41 43,67 102,42 ± 6,21 
 
 
In order to eliminate the matrix effect, measured E2 concentrations of patient samples 
(P and T) were normalized via substracting the measurement of the blank sample. 
Chromatogram examples of blank, standart and unknown sample are shown in 
Figure 3.12. 
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D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\250ppb-3.d Calibration 4 ; 308053 250.0000 0.0127
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\500 ppb-1.d Calibration 5 ; 663681 500.0000 0.0134
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\500 ppb-2.d Calibration 5 ; 661930 500.0000 0.0133
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Quantitative Analysis Calibration Report
Target Compound Testesterone
Calibration STD Cal Type Level Enabled Response Exp Conc RF
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\1 ppb-1.d Calibration 1 ; 9011 1.0000 0.1018
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\1 ppb-2.d Calibration 1 ; 9300 1.0000 0.1048
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\1 ppb-3.d Calibration 1 ; 8944 1.0000 0.0987
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\10ppb-1.d Calibration 2 ; 108542 10.0000 0.1182
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\10 ppb-2.d Calibration 2 ; 107830 10.0000 0.1177
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\10 ppb-3.d Calibration 2 ; 109947 10.0000 0.1191
D:\M ssHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\100 ppb-1.d Calibration 3 ; 1112880 100.0000 0.1192
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\100ppb-2.d Calibration 3 ; 1110750 100.0000 0.1181
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\100 ppb-3.d Calibration 3 ; 1104427 100.0000 0.1151
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\250 ppb-1.d Calibration 4 ; 2617695 250.0000 0.1095
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\250 ppb-2.d Calibration 4 ; 2638211 250.0000 0.1088
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\250ppb-3.d Calibration 4 ; 2628274 250.0000 0.1086
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\500 ppb-1.d Calibration 5 ; 5157422 500.0000 0.1044
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\500 ppb-2.d Calibration 5 ; 5066116 500.0000 0.1016
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\500 ppb-3.d Calibration 5 ; 5121681 500.0000 0.1067
D:\MassHunter\Data\Hormonlar
\Aromatase Activitiy Calibration-
2\1000 ppb-1.d Calibration 6 ; 10340118 1000.0000 0.1051
QuantReport_ISTD_Complete_B_06_00.xlsx                  Page 10 of 147 Printed at: 4:21 PM on: 6/10/2015
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Figure 3.12: Chromatograms of the blank, standart and patient samples. 
Overall, P had higher activity than N, on the other hand T showed approximately the 
same activity level with N (Figure 3.13).  Specific activity of aromatase (U.mg-1) was 
calculated for each sample, which are shown in Figure 3.14. The highest specific 
aromatase activity was 2582,40. 10-5U.mg-1 and observed in the peripheral tissue. 
The lowest specific aromatase activity was 3,17.10-5 U.mg-1 and observed in the 
tumor tissue.   
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Figure 3.13: The relative aromatase activity levels for tumor and peripheral tissue 
samples among patients. The activity of healthy tissue samples which is represented 
here as the dotted line were used as reference. Calculations were made according to 
LC-MS/MS measurements. Upper outliers were not shown. 
 
 
Figure 3.14: Specific activity of aromatase for tumor and peripheral tissue samples 
among patients. Calculations were made according to MS measurements. (*) 
Activity of P for patient 5# was 2582,40. 10-5 U.mg-1. (**) Activity of P for patient 
8# was 698,81. 10-5 U.mg-1. 
* ** x10
-5	
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The calculated activity of aromatase was higher in peripheral breast tissue of 70% of 
the patients compared to their tumor tissue and the difference was statistically 
significant (Z= -3.17, p= 0.002 [WSR]) (Figure 3.15-A). 80% of the measured 
aromatase activities were found to be consistent with CYP19A1 expression level 
results (Figure 3.15-B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: The distribution of aromatase activity levels calculated in regards of 
LC-MS/MS measurements among the patients: (A) P activity levels compared to T 
activity levels, the difference less than 2 fold was accepted as not changed; (B) 
Crossmatched results of activity and expression levels for P compared to T. Low: 
Low aromatase activity, High: High aromatase activity, Down: CYP19A1 
downregulated, Up: CYP19A1 upregulated. 
 
A 
B 
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When the expression levels of CYP17A1 and CYP19A1 were taken into 
consideration  together, the fold difference of aromatase activity between P and T 
was higher in IP group (Figure 3.16). However the difference did not reach statistical 
significance (p= 0.271 [MU]). 
 
Figure 3.16: P/T aromatase activity levels calculated via LC-MS/MS measurements 
among the estradiol decreasing (DP) and increasing (IP) expression pattern bearing 
groups. Upper outliers were not shown. 
 
The association of specific aromatase activity, measured via LC-MS/MS, and patient 
characteristics was also investigated. (Table 3.12). Oral contraceptive usage, 
presence of necrosis and absence of calcification were found significantly associated 
with high activity levels in peripheral tissue, where other known factors were not. 
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Table 3.12: Tissue aromatase activitiy levels measured via LC-MS/MS for different 
subgroups of patient characteristics. P < T: Peripheral tissue activity lower than 
tumor tissue activity, P > T: Peripheral tissue activity greater than tumor tissue 
activity. 
 
 
 
 
 
 
 
 
3.6 Lifetime Breast Cancer Risk Evaluation 
We investigated the association of CYP17A1, CYP19A1 expressions and aromatase 
activity levels with individual lifetime (up to age 90) breast cancer risk of the 
patients. The International Breast Cancer Intervention Study (IBIS) Breast Cancer 
Risk Evaluation Tool (www.ems-trials.org/riskevaluator/) was used in order to 
estimate the risk (Figure 3.17). We chose this model according to the National 
Cancer Institute (NCI) reccomendations. Personal factors and family history of 
cancer information was used. 
We detected a slight increase at the risk in patients who showed estradiol increasing 
pattern (Figure 3.18) and the difference was not statistically significant (p= 0.569 
[MU]). 
 
Patient characteristics P < T n (%) 
P > T 
n (%) 
Oral contraceptive use Yes 0 (0.00) 2 (100.00) 
No 4 (22.20) 14 (78.80) 
p-Value  (kappa) 0.0001 (0.054) 
Necrosis Yes 1 (16.70) 5 (83.30) 
No 3 (21.40) 11 (78.60) 
p-Value  (kappa) 0.006 (0.032) 
Calcification Yes 1 (23.10) 6 (76.90) 
No 3 (15.40) 10 (84.60) 
p-Value  (kappa) 0.012 (0.068) 
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Figure 3.17: Main screen of the IBIS Breast Cancer Risk Evaluation Tool program. 
 
 
Figure 3.18: Lifetime breast cancer  risk estimates among the estradiol decreasing 
(DP) and increasing (IP) expression pattern bearing groups . 
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We also observed the same risk escalation in cases which the specific activity of 
aromatase was higher at tumor tissue compared to its paired peripheral tissue (Figure 
3.19). The difference was not statistically significant according to both measurement 
methods (p= 0.850; p= 0.409 [MU]). 
 
Figure 3.19: The effect of aromatase activity levels calculated via RIA and LC-
MS/MS measurements over the lifetime breast cancer risk estimates 
3.7 Comparison of RIA and LC-MS/MS Methods 
We used two different methods for the measurement of the specific aromatase 
activity. Only two cases were measured differently, where higher activity levels in 
peripheral tissue were detected via RIA measurement (Table 3.13). An exact 
McNemar's test determined that there was no statistically significant difference in the 
proportion of aromatase activity measurements via RIA and LC-MS/MS (p = 0.500 
κ= 0.737 [MN]). 
Table 3.13: Crosstabulation table of LC-MS/MS and RIA measurements 
 
  LC-MS/MS 
measurement 
  P<T P>T 
RIA 
measurement 
P<T 4 0 
P>T 2 14 
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However the absolute values for specific aromatase activity calculated via RIA 
measurements were aproximately two times higher compared to LC-MS/MS 
measurement values (Figure 3.20). 
 
Figure 3.20: Average specific aromatase activity (U.mg-1) levels of tissue types 
calculated via RIA and LC-MS/MS measurements. 
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 DISCUSSION AND CONCLUSIONS  
Local productions of estrogens in breast as well as the effects of estrogens on 
progression of breast tumors are attractive areas of research.  Although a relationship 
between local estrogen production and the risk of breast cancer has been identified, 
at this point an accurate prediction of cancer risk in an individual is not possible. The 
variation in hormone levels within the different groups of people is yet to be 
understood. These results suggest additional mechanisms, such as up/down 
regulation of other enzymes involved in steroid synthesis pathway may influence 
intratumor levels of estrogens across individual tumor samples. Combined 
evaluations of these mechanisms including risk factors, such as family and 
reproductive histories, may lead not only to a more accurate assessment of risk in 
individual women but also to a better understanding of the role of estrogen in the 
pathogenesis of breast cancer (Clemons and Goss 2001, Li et al. 2005, Sidoni et al. 
2003).  
However, limited information is available on how these factors are related with gene 
expresion levels, which are considered as key factors in local estrogen production. 
Current study provides information about expression levels of CYP19A1 and 
CYP17A1 as well as aromatase activities within both tumor and and its peripheral 
adipose tissues compared to that in healthy breast tissue. The relationship between 
these expressions and activitiy status along with the breast health risk factors and 
clinicopathological parameters were also reported in order to investigate the effect of 
tumor progression. 
Estrogen arises from two sources in a postmenopausal woman with breast cancer. 
First, estrogen that arises from extraovarian body sites such as subcutaneous adipose 
tissue and skin reaches breast cancer by way of circulation in an endocrine manner. 
Second, estrogen locally produced in breast cancer tissue makes an impact via 
paracrine or intracrine mechanisms.  
Apparently, the major contribution for E2 biosynthesis comes from the adipose 
tissue. Aromatase expression is almost exclusive to immature adipocytes and adipose 
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tissue related fibroblasts of the breast (Sasano et al. 2009, Geisler 2003). These cells 
convert progesterone to androgens, and furtherly to estrogens, in particular, estradiol 
via P450c17 (CYP17A1) and aromatase (CYP19A1) (Figure 4.1). Estrogens can 
diffuse throughout the tissue, especially the adipose tissue of the breast, and enter the 
breast duct, where they stimulate epithelial cell proliferation (Simpson and Brown 
2013). Some however will enter the blood stream, circulate and then get taken up 
again by the adipose tissue, where they can mix with estrogen still present there and 
stimulate epithelial proliferation. Thus circulating estrogen levels will indeed be 
correlated with breast cancer risk, but this does not mean that they are the drivers of 
such risk; rather they reflect the local synthesis of estrogen within the adipose tissue, 
and within the breast in particular. Estrogens can act both directly or indirectly on 
human breast cancer cells to promote proliferation.  
 
Figure 4.1: The roles of CYP17A1 and CYP19A1 in invasive ductal breast 
carcinoma progression. 
Santen et al. (1997) have shown that stromal cells in breast carcinomas are the major 
source of estrogens in the tumor. There are other studies also found an elevation in 
aromatase expression in adipose stroma surrounding malignant breast epithelial cells 
which is regulated by complex cellular, molecular, and genomic mechanisms (Zhou 
et al, 2001; Agarwal et al, 1996). Independent studies were published from different 
laboratories where striking increases in aromatase enzyme activity and mRNA levels 
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signified in breast adipose tissue neighboring to tumor compared with those in distal 
adipose tissue or healthy breast adipose tissue (O’Neill et al., 1988; Bulun et al., 
1993; Harada et al., 1993; Reed et al., 1993; Sasano et al., 1994; Utsumi et al., 1996; 
Zhou et al., 1996). Prominently, the overall aromatase expression in breast adipose 
tissue in mastectomy specimens bearing a breast tumor was significantly higher than 
that in benign breast tissue removed for reduction mammoplasty (Agarwal et al 1995, 
Agarwal et al 1996, Agarwal et al 1997).  In the current study, CYP19A1 expression 
levels in peripheral tissues were nearly three times higher than the proximate tumor 
tissue (p=0.001 [WSR]), which is supporting the previous findings. In addition, 
higher aromatase activity in the peripheral tissues were observed compared to tumor 
tissues independent of measurement method. (p= 0.0004 [WSR] for RIA, p= 0.002 
[WSR] for MS).   
It is well-known that the estradiol concentration in plasma is significantly lower in 
postmenopausal compared to premenopausal women. Nevertheless, Pasqualini et al 
(1996), found that the levels of estradiol in breast cancer tissue were similar in 
premenopausal and postmenopausal women. Esteban et al (1992),  found that 15 
(40%) of 38 breast cancers demonstrated significant immunoreactivity for aromatase. 
Utilizing an assay for aromatase activity that quantifies production of tritiated water 
release from 1-tritiated-androstenedione, Lipton et al (1992) found measurable 
aromatase activity in 69% of 113 breast cancers.  Another study performed by Yue et 
al (1998), who developed a model in which aromatase and sham-transfected MCF-7 
cells were inoculated into ovariectomized nude mice, documented the pathologic 
significance of local aromatase activity in breast cancers in postmenopausal women. 
Heterotransplants in which aromatase-transfected MCF-7 cells were implanted in one 
flank and sham-transfected cells in the other flank demonstrated that the tumor 
weight was 7.6 fold larger and the estradiol concentration 3 to 4 fold higher in the 
aromatase transfected tumors. Our aromatase activity measurements detected the 
highest activity in peripheral tissue group and supports previous findings. Overall, 
peripheral aromatase activity was approximately 4 fold higher than the control 
(premenapausal) group. Furthermore, the tumor group showed almost the same level 
of aromatase activity with controls (Figure 3.6 and 3.12). Thus, we can speculate that 
the source of local estradiol, which plays a major role in proliferation of malignant 
epithelial breast cancer cells, depends on the power of local aromatization activity.  
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Local steroid biosynthesis and metabolism of exogenous ligands adds further 
complexity to the balance between estrogen and androgen hormone action, and it is 
now  recognized as a crucial aspect contributing to the progression of estrogen driven 
breast carcinomas (Risbridger et al, 2010). For example, estrogen receptor-α (ERα) is 
considered as the primary proliferative and survival stimulus in breast epithelial 
cells. However, this stimulating effect compansated by androgen action through the 
androgen receptor (AR), which has direct inhibitory effects on cell survival and can 
inhibit the proliferative actions of estrogen. The expression of progesterone receptor 
(PR) increases with this estrogen action. Progresterone action  can  both stimulate 
and  inhibit the proliferation in breast cancer cells (Figure 4.2). Some evidence 
suggests that androgen action might also inhibit the PR signalling pathway but this 
remains uncertain (Risbridger et al, 2010). The impact of CYP17A1 is becoming  
important in this context where its activity determines the fate of progesterone. 
Therefore, trying to explain estardiol’s effect on estrogen driven breast carcinomas 
based on only local aromatase expression and activity may not reflect the reality. 
Previously our group showed how the different allele combination of CYP17A1 and 
CYP19A1 genes might effect on breast cancer risk (Tuzuner et al 2010). In current 
study, we assumed combination of upregulated and unaltered CYP17A1 and  
CYP19A1 expression levels to increase estrogen production.  Although, this pattern 
coralates with higher aromatase activity levels in peripheral tissues compared to 
tumor tissues, it did not reach statistical significance (Figure 3.9 and 3.15). The 
expression levels of other critical enzymes such as 17β-HSD and 5α-reductase 
should also taken into consideration in order to get results that are more reliable.   
Postmenopausal women’s ovaries cease to synthesize estrogens; however, the risk of 
breast cancer continues to increase with age. The main reason is the continuous 
exposure of estrogen to breast tissue in postmenopausal women (Zhu and Coney 
1998). Although, we did not observe an effect of age over expression levels or 
aromatase acivity in our relatively small (n= 20) study population.  
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Figure 4.2: Hormone interactions in breast epithelial cells. The dashed line represent 
a putative inhibitory effect.  PRG: Progesterone; TES: Testosterone, E: Estrogens; 
DHT: 5α-dihydrotestosterone. 
Miyoshi et al. (2003) observed higher CYP17A1 mRNA levels in small tumors (≤ 2 
cm), suggesting that CYP17A1 mRNA upregulation might play some role in the 
early stage of tumor development. In the current study most of the patients (75%) 
had late onset breast cancer, which may be associated with unaltered CYP17A1 
expression in peripheral tissues and slight down regulation in tumors. On the 
contrary, in peripheral tissues at the early onstage of the disease, when both CYPs 
were together, they appeared to decrease of local estrogen production via regulating 
the levels of expression (p=0.021 [MN]). It was also possible to observe this via 
histological grade parameter where high-grade tumor tissues were found down 
regulated (p= 0.012 [MN]), while grade I tumor tissues exhibited higher levels of 
CYP17A1 expression (p= 0.013 [MN]). Thus, it can be speculated that tumor tissues 
are more active for estrogen production than peripheral tissues in the early phases of 
breast cancer and later on production site shifts to peripheral fibroblasts.  
The most significant prognostic factor for women with breast cancer is axillary 
lymph node invasion status (Donegan 1997). Nodal metastases double the risk of 
distant disease and the presence or absence of axillary lymph node metastases is also 
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a determining factor for the use of systemic adjuvant chemotherapy (Hortobagyi and 
Buzdar 1995). Here CYP19A1 in neighboring adipose tissues were highly expressed 
in all cases with positive axillary invasion (p= 0.012 [MN]), thus it may be suggested 
as an additional parameter for such decisions like adjuvant chemotherapy. 
Upon outgrowth of their oxygen supply, emerging tumors develop hypoxic and 
eventually necrotic regions believed to be the direct result of chronic ischemia 
caused by vascular collapse when the rate of tumor cell growth exceeds that of 
angiogenesis. Necrosis in invasive carcinoma of the breast has been correlated with 
the concomitant angiogenesis, development of high vascular density, and increased 
levels of focal macrophage infiltration driven by chemotactic factors. Necrosis at the 
tumor center is a common feature of aggressive breast cancer and has been 
associated with poor prognosis. Our data showed association of higher aromatase 
activity in peripheral tissue compared to its paired tumor tissue among the cases with 
necrosis (Table 3.9 and 3.12). Invasive ductal breast carcinoma cases so closely 
mimicking ductal carcinoma insitu (DCIS) with central necrosis that on initial 
morphological analysis these foci of tumors were labeled as DCIS (high grade, 
comedo). However on further histological work up and by using IHC for 
myoepithelial markers it was later confirmed that these were foci of invasive ductal 
carcinoma breast with central necrosis (Pervez and Khan 2007). Evaluating of 
aromatase activity levels with necrosis status may be an asset for discrimination of 
such cases. 
The presence of calcification clusters is an important sign for the detection of early 
breast carcinoma. An early sign of 30–50% of breast cancer detected 
mammographically is the appearance of clusters of fine, granular microcalcification, 
and 60–80% of breast carcinomas reveal calcifications upon histological 
examinations (Cheng et al 2003).We observed higher aromatase activity in peripheral 
tissue compared to tumor tissue in the 77% of the cases with calcification (p=0,012). 
The underlying molecular mechanism was not clear, thus the effect should be 
investigated furtherly with greater study groups.    
The expression of ER, PR and HER2 are key in determining prognosis and 
management. Especially both ER positive and PR positive (rather than only ER 
positive) tumors may respond better to hormonal therapy. In addition, absence of PR 
expression in primary breast cancer is strongly and independently associated with 
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poor prognosis (Purdie et al. 2014). Association between weak PR and low 
expression levels of both CYP17A1 and CYP19A1 in tumor tissues that we observed 
in this study, showed that these expression levels could be taken into consideration to 
identify patients who might benefit additional adjuvant chemotherapy, extended 
endocrine therapy and/or treatments targeting growth factor receptor pathways. 
Although there are preferred regimens in hormone treatment, such as aromatase 
inhibitors or ER blockers (Fisher et al. 2005), predicting which treatment could be 
most profitable for a particular patient is yet unclear. Evaluating the expressional 
levels of certain CYPs, due to their key role in estrogen synthesis, may be valuable 
for selecting the right treatment in addition to the conventional approach.  
CYP19A1 up regulation in peripheral tissues is associated with familial incidences of 
cancer, breast cancer in particular (p= 0.039, p= 0.004 [MN]). Accumulation of 
different genotypes for different mutations of CYP19A1 may affect expression 
levels, thus altering aromatase activity and and subsequently affecting the 
endogenous estrogen levels (Surekha et al. 2014, Tüzüner et al. 2010). However, we 
did not observe a significant effect of this factor to the aromatase activity difference 
among the tissue groups.  
Expresion patterns of CYP17A1 and CYP19A1 may influence the degree of estrogen 
exposure on breast epithelial cells. Since the effects of the various hormonal risk 
factors might dependen on the expression levels in different tissues, this possible 
diversity was of interest. Patients bearing “high risk” factors such as early onset of 
menstruation, nullparity and being older than 50 years old produced low levels of 
both expression and activity for CYP19A1 in P and T, which was not in agreement 
with the previous findings (Clemons and Goss 2001). However late age at pregnancy 
and the association with upregulation of aromatase expression in P, supported 
previous results (p=0.039 [MN]) (Russo et al. 2005, Britt et al. 2007). We also 
observed higher aromatase activity in P compared to T in this group, although the 
kappa value is negative. Pregnancy may have direct effect on immature adipocytes, 
causing them to differentiate and maturate which can no longer express aromatase. 
Nevertheless, tumor cells prevent these fibroblasts to become mature adipocytes, 
therefore women who had children after 30 years of age are probably more prone to 
this effect. 
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The growing public awareness of breast cancer and its risk factors, coupled with the 
availability of medical and surgical risk reduction options, has led to many women 
consulting their doctors regarding their breast cancer risk. Multiple prediction models 
have been developed to assist with breast cancer risk prediction efforts. We aimed to 
investigate if there may be an association between the outcome of a such model and 
expression and activity levels. The Tyrer-Cuzick model (IBIS) (Tyrer et al 
2004),  was used in our study since it is the only risk assessment model that explicitly 
accounts for differences in breast cancer risk, given the presence of atypical 
hyperplasia as well as extensive family history information, endogenous estrogen 
exposure, and benign breast disease (Amir et al 2003). We observed that the higher 
the lifetime risk were associated with estradiol increasing expression pattern. 
However, the lifetime risk was found to be decreased in patients who had higher 
specific activity of aromatase at peripheral tissue compared to its paired tumor tissue 
(Figure 3.18). The possible explanation of this discrepancy is the unequal distribution 
of the patients between groups where only few patients have higher specific 
aromatase activity in their tumor tissue compared to peripheral tissue (RIA n=2, LC-
MS/MS n=4) (Table 3.12). CYP17A1 and CYP19A1 expression alterations may be 
considered as factors for such risk model in the future if their effect significantly 
exhibited via studies with greater sample sized.  
In current study we have developed two different method, RIA and LC-MS/MS 
based, for the measurement of the specific aromatase activity of the microsomal 
fraction extracted from the breast adipose and tumor tissue. One of the aims in this 
study was to determine whether similar RIA and LC-MS/MS results would be 
attained or not. Although the RIA overestimated E2 concentrations (approximately 2 
fold) (Figure 3.19) matched to LC–MS/MS; the calculated aromatase activity ratio of  
peripheral adipose and tumor tissue was aproximately same in both methods. The 
observed discrepancy between methods for the samples was most likely due to the 
sample matrix and the specificity of the RIA kit antibody. Many studies have 
indicated that RIA exhibits poor specificity for steroids with several interferences 
and severe matrix effects. Antibodies used for RIA can cross-react during the 
recognition of steroids, which are present in low concentrations in complex 
biological fluids (Hoofnagle and Wener 2009, Stanczyk and Clarke 2010, Stanczyk 
et al 2007). On the other hand, the primary matrix effect associated with LC-MS/MS 
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methods is ion suppression or enhancement caused by the co-eluting matrix 
components. This effect can be caused by both inorganic and organic endogenous 
substances, including salt, carbohydrates, amines, urea, lipids, peptides, and 
metabolites (Antignac et al 2005). A possible explanation is that the matrix 
compounds compete with analyte for the limited charge on the droplet surfaces and, 
thus, affect ionization of analyte. Another possible explanation is that interfering 
compounds increase the droplet’s viscosity and surface tension, thereby decreasing 
solvent evaporation rate. As a result, a lesser amount of analyte is able to reach the 
gas phase. It has also been suggested that nonvolatile materials in the matrix can 
decrease the rate of droplet formation though coprecipitation of the analyte and, 
therefore, prevent droplets from reaching the critical radius required for gas phase 
ions to be emitted (Chiu et al 2010).   
Another drawback of RIA observed in current study was the difficulties in 
optimization of a commercial kit for tissue extract samples. In addition the short 
shelf life and the special requirements for the storage and waste disposal could be 
reffered as disadvantages, hence the method depends on a radioactive compound 
(125I).  
It appears, the in-house LC-MS/MS method more advantegous compared to RIA. 
Although we observed the possible ion suppression related loss of sensitivity 
compared to RIA, after optimization of the conditions and the proper calibration of 
the analytes, we managed to detect and quantify the formed E2 via microsomal 
fraction of the tissue extract with higher selectivity and improved signal-to-noise 
ratios. The developed method did not require derivatization of the analytes (E1, E2 
and TES), therefore faster and simpler and displays high selectivity and accuracy 
compared to RIA. Considering the tandem mass spectrometry hyphenated to liquid 
chromatography separation systems has developed to an important technology in 
clinical chemistry  (Vogeser and Seger, 2008), the current method has the potential to 
be further developed to a commonly applied high-throughput technique for 
aromatase activity measurement.  
Lifetime exposure to estrogen and other physiological factors, including 
environmental exposures, could play a critical role in the etiology of breast cancer. 
Finding effective therapy approaches for cancer is crucial, as is early diagnosis. The 
ultimate goal will be to have accurate molecular profiling of patients with estrogen 
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driven breast cancer that can personalise treatment pathways, which in turn will 
enhance the effectiveness of current strategies. In conclusion, this study suggests that 
evaluation of various clinicopathological and disease risk factors along with the 
expression levels of CYP17A1 and CYP19A1 and the aromatase activity levels at 
breast tumor microenvironment might help clinicians to decide on treatment 
startegies and diagnosis for individual cases, particularly with postmenapausal status. 
However, future studies must be conducted using greater sample size and addition of 
other key enzyme activities evaluations in streidogenesis pathway which effect local 
estrogen levels for confirmation and gettting more strong and reliable results.  
 
 
 
 
 
 
 
71 
 
 
REFERENCES 
Abul-Hajj, Y. J., Iverson, R., Kiang, D. T. (1979). Aromatization of androgens by 
human breast cancer. Steroids, 33 (2), 205-222. 
Agarwal, V. R., Bulun S. E., Simpson E. R. (1995). Quantitative detection of 
alternatively spliced transcripts of the aromatase cytochrome P450 
(CYP19) gene in aromatase-expressing human cells by competitive 
RT-PCR. Mol Cell Probes, 9 (6), 453-464. 
Agarwal, V. R., Bulun, S. E., Leitch, M., Rohrich, R., Simpson, E. R. (1996). Use 
of alternative promoters to express the aromatase cytochrome P450 
(CYP19) gene in breast adipose tissues of cancer-free and breast 
cancer patients. J Clin Endocrinol Metab, 81 (11), 3843-3849. 
Agarwal, V. R., Ashanullah, C. I., Simpson, E. R., Bulun, S. E. (1997). 
Alternatively spliced transcripts of the aromatase cytochrome P450 
(CYP19) gene in adipose tissue of women. J Clin Endocrinol Metab, 
82 (1), 70-74. 
Aiginger, P., Kolbe, H., Kuhbock, J., Spona, J., Geyer, G. (1981). The 
endocrinology of testicular germinal cell tumors. Acta Endocrinol, 97, 
419–426. 
Akhtar, M., Calder, M. R., Corina, D. L., Wright, J. N. (1982). Mechanistic 
studies on C-19 demethylation in oestrogen biosynthesis. Biochem J, 
201 (3), 569-580. 
Allen, N. E., Beral, V., Casabonne, D., Kan, S. W., Reeves, G. K., Brown, A., ….. 
Million Women Study Collaborators (2009). Moderate alcohol 
intake and cancer incidence in women. J Natl Cancer Inst, 101 (5), 
296-305. 
Amir, E., Evans, D. G., Shenton, A., Lalloo, F., Moran, A., Boggis, C., …... 
Howell, A. (2003). Evaluation of breast cancer risk assessment 
packages in the family history evaluation and screening programme. J 
Med Genet, 40 (11), 807-814. 
Antignac, J. P., De Wasch, K., Monteau, F., De Brabander, H., Andre, F., Le 
Bizec, B. (2005). The ion suppression phenomenon in liquid 
chromatography - mass spectrometry and its consequences in the field 
of residue analysis.  Analytica Chimica Acta, 529 (1-2), 129–136.  
72 
 
Beral, V., Million Women Study Collaborators. (2003). Breast cancer and 
hormone-replacement therapy in the Million Women Study. Lancet, 
362 (9382), 419-427. 
Bloom, H. J., Richardson, W. W. (1957). Histological grading and prognosis in 
breast cancer; a study of 1409 cases of which 359 have been followed 
for 15 years. Br J Cancer, 11 (3), 359-377. 
Britt, K., Ashworth, A., Smalley, M. (2007). Pregnancy and the risk of breast 
cancer. Endocr Relat Cancer, 14 (4), 907-933. 
Bulun, S. E., Price, T. M., Aitken, J., Mahendroo, M. S., Simpson, E. R. (1993). 
A link between breast cancer and local estrogen biosynthesis 
suggested by quantification of breast adipose tissue aromatase 
cytochrome P450 transcripts using competitive polymerase chain 
reaction after reverse transcription. J Clin Endocrinol Metab, 77 (6), 
1622-1628. 
Bulun, S. E., Noble, L. S., Takayama, K., Michael, M. D., Agarwal, V., Fisher, 
C., ….. Simpson, E. R. (1997). Endocrine disorders associated with 
inappropriately high aromatase expression. J Steroid Biochem Mol 
Biol, 61 (3-6), 133-139. 
Bulun, S. E., Simpson, E. R. (2008). Aromatase expression in women's cancers. 
Adv Exp Med Biol, 630, 112-132. 
Capper, C. P., Larios, J. M., Sikora, M. J., Johnson, M. D., Rae, J. M. (2016). 
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist 
activity in breast cancer. Breast Cancer Res Treat, 157 (1), 23-30.  
Carruba, G. (2009). Aromatase in nontumoral and malignant human liver tissues 
and cells. Ann N Y Acad Sci, 1155, 187-193.  
Chen, Y., Gammon, M. D., Teitelbaum, S. L., Britton, J. A., Terry, M. B., 
Shantakumar, S., ….. Ahsan, H. (2008). Estrogen biosynthesis gene 
CYP17 and its interactions with reproductive, hormonal and lifestyle 
factors in breast cancer risk: results from the Long Island Breast 
Cancer Study Project. Carcinogenesis, 29 (4), 766-771.  
Cheng, H. D., Cai, X., Chen, X., Hu, L., Lou, X. (2003). Computer-aided detection 
and classification of microcalcification in mammgrams: a survey. 
Pattern Recognition, 36, 2967-2991.  
Chiu, M. L., Lawi, W., Snyder, S. T., Wong, P. K., Liao, J. C., Gau, V. (2010). 
Matrix Effects-A Challenge Toward Automation of Molecular 
Analysis. Jala, 15 (3), 233–242. 
73 
 
Clemons, M., Goss, P. (2001). Estrogen and the risk of breast cancer. N Engl J Med, 
344 (4), 276-285. 
Cole, P. A., Robinson, C. H. (1991). Mechanistic Studies on a Placental Aromatase 
Model Reaction. Journal of the American Chemical Society, 113 (21), 
8130-8137. 
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. 
A., ….. Narod S. A. (2007). Triple-negative breast cancer: clinical 
features and patterns of recurrence. Clin Cancer Res, 13 (15 Pt 1), 
4429-4434. 
Donegan, W. L. (1997). Tumor-related prognostic factors for breast cancer. CA 
Cancer J Clin, 47, 28–51. 
Edge, S. B. (2010). AJCC Cancer Staging Manual. In D. R. Byrd, C. C. Compton, A. 
G. Fritz, F. L. Greene, A. Trotti, (Eds.), Breast (7th ed., Vol. 7, pp. 
419–460). New York: Springer. 
Elston, C. W., Ellis, I. O. (2002). Pathological prognostic factors in breast cancer. I. 
The value of histological grade in breast cancer: experience from a 
large study with long-term follow-up. Histopathology, 41 (3A), 154-
161. 
Esteban, J. M., Warsi, Z., Haniu, M., Hall, P., Shively, J. E., Chen, S. (1992). 
Detection of intratumoral aromatase in breast carcinomas. Am J 
Pathol, 140, 337-343. 
Feigelson, H. S., Coetzee, G. A, Kolonel, L. N., Ross, R. K, Henderson, B. E. 
(1997). A polymorphism in the CYP17 gene increases the risk of 
breast cancer. Cancer Res, 57 (6), 1063-1065. 
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., ….. 
Bray, F. (2015). Cancer incidence and mortality worldwide: sources, 
methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136 
(5), E359-86. 
Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., 
Robidoux, A., ….. Wolmark, N. (2005). Tamoxifen for the 
prevention of breast cancer: current status of the National Surgical 
Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst, 97 
(22), 1652-1662. 
Geisler, J. (2003). Breast cancer tissue estrogens and their manipulation with 
aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol, 86 
(3-5), 245-253. 
74 
 
Genestie, C., Zafrani, B., Asselain, B., Fourquet, A., Rozan, S., Validire, P., ….. 
Sastre-Garau, X. (1998). Comparison of the prognostic value of 
Scarff-Bloom-Richardson and Nottingham histological grades in a 
series of 825 cases of breast cancer: Major importance of the mitotic 
count as a component of both grading systems. Anticancer Research 
18 (1B), 571-576 
Geyer, F. C., Marchio, C., Reis-Filho, J. S. (2009). The role of molecular analysis 
in breast cancer. Pathology, 41, 77–88.  
Haagensen, C. D. (1986). Diseases of The Breast. Philadelphia: W.B. Saunders 
Company.  
Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., 
Badve, S., ….. Wolff, A. C. (2010). American Society of Clinical 
Oncology/College of American Pathologists guideline 
recommendations for immunohistochemical testing of estrogen and 
progesterone receptors in breast cancer. J Clin Oncol, 28, 2784-2795.  
Harada, N., Yamada, K., Saito, K., Kibe, N., Dohmae, S., Takagi, Y. (1990). 
Structural characterization of the human estrogen synthetase 
(aromatase) gene. Biochem Biophys Res Commun, 166, 365–372 
Harada, N., Utsumi, T., Takagi, Y. (1993). Tissue specific expression of the human 
aromatase cytochrome P450 gene by alternative use of multiple exons 
I and promoters and switching carcinogenesis. Proc Natl Acad Sci, 90, 
11312-11316.  
Helzlsouer, K. J., Huang, H. Y., Strickland, P. T., Hoffman, S., Alberg, A. J., 
Comstock, G. W., Bell, D. A. (1998). Association between CYP17 
polymorphisms and the development of breast cancer. Cancer 
Epidemiol Biomarkers Prev, 7, 945-949. 
Hoofnagle, A., N., Wener, M. H. (2009). The fundamental flaws of immunoassays 
and potential solutions using tandem mass spectrometry. J Immunol 
Methods, 347, 3–11  
Hortobagyi, G. N., Buzdar, A. U. (1995). Current status of adjuvant systemic 
therapy for primary breast cancer: progress and controversy. CA 
Cancer J Clin, 45, 199–226 
Hu, R., Dawood, S., Holmes, M. D., Collins L. C., Schnitt, S. J., Cole, K., ….. 
Tamimi, R. M. (2011). Androgen receptor expression and breast 
cancer survival in postmenopausal women. Clinical Cancer Research, 
17, 1867–1874.  
75 
 
Jefcoate, C. R., Liehr, J. G., Santen, R. J., Sutter, T. R., Yager, J. D., Yue, W., 
….. Berstein, L. (2000). Tissue-specific synthesis and oxidative 
metabolism of estrogens. J Natl Cancer Inst Monogr, 27, 95-112. 
Jongen, V. H., Hollema, H., Van Der Zee, A. G., Heineman, M. J. (2006). 
Aromatase in the context of breast and endometrial cancer. A review. 
Minerva Endocrinol, 31 (1), 47- 60.  
Kaufman, B., Laitman, Y., Ziv, E., Hamann, U., Torres, D., Lahad, E. L., ….. 
Friedman, E. (2010). The CYP17A1 -34T > C polymorphism and 
breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast 
Cancer Res Treat, 126 (2), 521-527. 
Kovacic, S. C. A., Simpson, E. R., Clyne, C. D. (2004). Inhibition of aromatase 
transcription via promoter II by short heterodimer partner in human 
preadipocytes. Mol Endocrinol, 18, 252–259. 
Köse M. R. (2015). The Ministry Of Health Of Turkey Health Statistics Yearbook 
2014. In B. B. Başara, C. Güler, G. K. Yentür (Eds.), Morbidity (Vol. 
3, pp. 25-40). Retrieved from http://www.saglik.gov.tr/TR/dosya/1-
100379/h/eng-yillik.pdf 
Landis, J. R., Koch, G. G. (1977). The measurement of observer agreement for 
categorical data. Biometrics 33, 159-174.  
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy A. B., 
Shyr, Y., Pietenpol, J. A. (2011). Identification of human triple-
negative breast cancer subtypes and preclinical models for selection of 
targeted therapies. Journal of Clinical Investigation, 121, 2750–2767. 
Li, C. I., Uribe, D. J., Daling, J. R. (2005). Clinical characteristics of different 
histologic types of breast cancer. Br J Cancer, 93, 1046–1052. 
Lipton, A., Santen, R. J., Santner, S. J., Harvey, H. A., Sanders, S. I., Matthews, 
Y. L. (1992). Prognostic value of breast cancer aromatase. Cancer, 70 
(7), 1951–1955.  
Livak, K. J., Schmittgen, T. D. (2001). Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) 
Method. Methods, 25 (4), 402-408. 
Martucci, C. P., Fishman, J. (1993). P450 enzymes of estrogen metabolism. 
Pharmacol Ther, 57 (2-3), 237-257. 
Mendelson, C. R., Evans, C. T., Simpson, E. R. (1987). Regulation of aromatase in 
estrogen-producing cells. J Steroid Biochem, 27 (4-6), 753-757. 
76 
 
Meng, L., Zhou, J., Hironobu, S., Suzuki, T., Zeitoun, K., Bulun, S. (2001). TNF-
alpha and IL-11 secreted by malignant breast epithelial cells inhibit 
adipocyte differentiation by selectively downregulating C/EBPalpha 
and PPARgamma: mechanism of desmoplastic reaction. Cancer 
Research, 61, 2250–2255.  
Miyoshi, Y., Noguchi S. (2003). Polymorphisms of estrogen synthesizing and 
metabolizing genes and breast cancer risk in Japanese women. Biomed 
Pharmacother, 57 (10), 471-481.  
Monninkhof, E. M., Elias, S. G., Vlems, F. A., van der Tweel, I., Schuit, A. J., 
Voskuil, D. W., ….. TFPAC. (2007). Physical activity and breast 
cancer: a systematic review. Epidemiology, 18 (1), 137-157. 
Newman, A. E., Chin, E. H., Schmidt, K. L., Bond, L., Wynne-Edwards, K. E, 
Soma, K. K. (2008). Analysis of steroids in songbird plasma and 
brain by coupling solid phase extraction to radioimmunoassay. Gen 
Comp Endocrinol, 155 (3), 503-510.  
O'Neill, J. S., Elton, R. A., Miller, W. R. (1988). Aromatase activity in adipose 
tissue from breast quadrants: a link with tumor site. British Medical 
Journal, 296, 741–743.  
Ozmen, V. (2008). Breast cancer in the World and Turkey. J Breast Health, 4, 6-12. 
Pasqualini, J. R., Chetrite, G., Blacker, C., Feinstein, M. C., Delalonde, L., 
Talbi, M., Maloche, C. (1996). Concentrations of estrone, estradiol, 
and estrone sulfate and evaluation of sulfatase and aromatase activities 
in pre- and postmenopausal breast cancer patients. Journal of Clinical 
Endocrinology and Metabolism, 81, 1460–1464.  
Parvez, S., Khan, H. (2007). Infiltrating ductal carcinoma breast with central 
necrosis closely mimicking ductal carcinoma in situ (comedo-type): A 
case series. J Med Case Rep, 1, 83. 
Picado-Leonard, J., Miller, W. L. (1987). Cloning and sequence of the human gene 
for P450c17 (steroid 17a-hydroxylase/17,20 lyase): similarity with the 
gene for P450C21. DNA, 6, 439 - 448.  
Prat, A., Perou, C. M. (2011). Deconstructing the molecular portraits of breast 
cancer. Mol Oncol, 5 (1), 5-23.  
Purdie, C.A., Quinlan, P., Jordan, L. B., Ashfield, A., Ogston, S., Dewar, J. A., 
Thompson, A. M. (2014). Progesterone receptor expression is an 
independent prognostic variable in early breast cancer: a population-
based study. Br J Cancer, 110 (3), 565-572.  
77 
 
Reed, M. J., Topping, L., Coldham, N. G., Purohit, A., Ghilchik, M. W., James, 
V. H. (1993). Control of aromatase activity in breast cancer cells: the 
role of cytokines and growth factors. J Steroid Biochem Mol Biol, 44 
(4-6), 589-596. 
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., Bull, D., Million 
Women Study Collaboration. (2007). Cancer incidence and 
mortality in relation to body mass index in the Million Women Study: 
cohort study. BMJ, 335 (7630), 1134.  
Risbridger, G. P., Davis, I. D., Birrell, S. N., Tilley, W. D. (2010). Breast and 
prostate cancer: more similar than different. Nat Rev Cancer, 10 (3), 
205-212.  
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E. Jr., 
Davidson, N. E., ….. Wolmark, N. (2005). Trastuzumab plus 
adjuvant chemotherapy for operable HER2-positive breast cancer. N 
Engl J Med, 353 (16), 1673-1684. 
Russo, J., Moral, R., Balogh, G. A., Mailo, D., Russo, I. H. (2005). The protective 
role of pregnancy in breast cancer. Breast Cancer Res, 7, 131–142. 
Ryan, K. J. (1959). Biological aromatization of steroids. J Biol Chem, 234 (2), 268-
272. 
Santen, R. J., Santner, S. J., Pauley, R. J., Tait, L., Kaseta, J., Demers, L. M., 
….. Wang, J. P. (1997). Estrogen production via the aromatase 
enzyme in breast carcinoma: which cell type is responsible? J Steroid 
Biochem Mol Biol, 61 (3-6), 267-271. 
Santen, R. J. (2007). The oestrogen paradox: a hypothesis. Endokrynol Pol, 58 (3), 
222-7. 
Santen, R. J., Brodie H., Simpson E. R., Siiteri P. K., Brodie A. (2009). History 
of aromatase: saga of an important biological mediator and therapeutic 
target. Endocr Rev, 30 (4), 343-375. 
Sasano, H., Nagura, H., Harada, N., Goukon, Y., Kimura, M. (1994). 
Immunolocalization of aromatase and other steroidogenic enzymes in 
human breast disorders. Human Pathology, 25, 530–535.  
Sasano, H., Miki, Y., Nagasaki, S., Suzuki, T. (2009). In situ estrogen production 
and its regulation in human breast carcinoma: from endocrinology to 
intracrinology. Pathol Int, 59, 777–789. 
Sebastian, S., Bulun, S. E. (2001). A highly complex organization of the regulatory 
region of the human CYP19 (aromatase) gene revealed by the human 
genome project. J Clin Endocrinol Metab, 86, 4600–4602.  
78 
 
Setiawan, V. W., Schumacher, F. R., Haiman, C. A., Stram, D. O., Albanes, D., 
Altshuler, D., ….. Chanock, S. J. (2007). CYP17 genetic variation 
and risk of breast and prostate cancer from the National Cancer 
Institute Breast and Prostate Cancer Cohort Consortium (BPC3). 
Cancer Epidemiol Biomarkers Prev, 16, 2237–2246. 
Sidoni, A., Cavaliere, A., Bellezza, G., Scheibel, M., Bucciarelli, E. (2003). Breast 
cancer in young women: clinicopathological features and biological 
specificity. Breast, 12, 247–250. 
Simpson, E. R., Brown, K. A. (2013). Obesity and breast cancer: role of 
inflammation and aromatase. J Mol Endocrinol, 51 (3), 51-59.  
Simpson, E. R., Mahendroo, M. S., Means, G. D., Kilgore,  M. W., Hinshelwood, 
M. M., Graham-Lorence, S., ..... Bulun, S. E. (1994). Aromatase 
cytochrome P450, the enzyme responsible for estrogen biosynthesis. 
Endocrine Reviews, 15, 342–355.  
Simpson, E. R., Clyne, C., Rubin, G., Boon, W. C., Robertson, K., Britt, K., ..... 
Jones, M. (2002). Aromatase--a brief overview. Annu Rev 
Physiol, 64, 93–127.  
Simpson, E. R. (2003). Sources of estrogen and their importance. J Steroid Biochem 
Mol Biol, 86 (3-5), 225-230.  
Simpson, E. R., Misso, M., Hewitt, K. N., Hill, R. A., Boon, W. C., Jones, M. E., 
….. Clyne, C. D. (2005) Estrogen—the good, the bad, and the 
unexpected. Endocr Rev, 26, 322–330. 
Sohl, C. D., Guengerich, F. P. (2010). Kinetic analysis of the three-step steroid 
aromatase reaction of human cytochrome P450 19A1. J Biol Chem, 
285 (23), 17734-17743.  
Sotiriou, C., Pusztai, L. (2009). Gene-expression signatures in breast cancer. N Engl 
J Med, 360 (8), 790-800. 
Stanczyk, F. Z., Clarke, N. J. (2010). Advantages and challenges of mass 
spectrometry assays for steroid hormones. J Steroid Biochem Mol 
Biol, 121, 491–495.  
Stanczyk, F. Z., Lee, J. S., Santen, R. J. (2007). Standardization of steroid hormone 
assays: why, how, and when? Cancer Epidemiol Biomarkers Prev, 16, 
1713–1719.  
Surekha, D., Sailaja, K., Rao, D. N., Padma, T., Raghunadharao, D., 
Vishnupriya, S. (2014). Association of CYP19 polymorphisms with 
breast cancer risk: a case-control study. J Nat Sci Biol Med, 5, 250–
254. 
79 
 
Tekmal, R., Gill, K. N. K., Fowler, K. (1999). Aromatase overexpression and 
breast hyperplasia, an in vivo model--continued overexpression of 
aromatase is sufficient to maintain hyperplasia without circulating 
estrogens, and aromatase inhibitors abrogate these preneoplasatic 
changes in mammary glands. Endocrine-Related Cancer, 6, 307–314.  
Tuzuner, B. M., Ozturk, T., Kisakesen, H. I., Ilvan, S., Zerrin, C., Ozturk, O., 
Isbir, T. (2010). CYP17 (T-34C) and CYP19 (Trp39Arg) 
polymorphisms and their cooperative effects on breast cancer 
susceptibility. In Vivo, 24, 71–74. 
Tyrer, J., Duffy, S. W., Cuzick, J. (2004). A breast cancer prediction model 
incorporating familial and personal risk factors. Stat Med, 23 (7), 
1111-1130. 
Utsumi, T., Harada, N., Maruta, M., Takagi, Y. (1996). Presence of alternatively 
spliced transcripts of aromatase gene in human breast cancer. J Clin 
Endocrinol Metab, 81, 2344-2349. 
Vogel, V. G. (2008). Epidemiology, genetics, and risk evaluation of postmenopausal 
women at risk of breast cancer. Menopause, 15 (4 Suppl), 782-789. 
Vogeser, M., Seger, C. (2008). A decade of HPLC-MS/MS in the routine clinical 
laboratory--goals for further developments. Clin Biochem, 41 (9), 649-
662.  
Voutilainen, R., Miller, W. L. (1986). Developmental expression of genes for the 
stereoidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 
alpha-hydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the 
human fetus. J Clin Endocrinol Metab. 63 (5), 1145-1150. 
Wang, H., Li, R., Hu, Y. (2009). The alternative noncoding exons 1 of aromatase 
(Cyp19) gene modulate gene expression in a posttranscriptional 
manner. Endocrinology, 150 (7), 3301-3307.  
Haagensen, C. D. (1986). Diseases of The Breast. Philadelphia: W.B. Saunders 
Company.  
Lakhani, S. R., Ellis, I. O., Schnitt, S. J., Tan, P. H., van de Vijver, M. J. (2012). 	
IARC WHO Classification of Tumours, No: 4. Geneva: WHO Press. 
Yaghjyan, L., Colditz, G. A. (2011). Estrogens in the breast tissue: a systematic 
review. Cancer Causes Control, 22, 529-540. 
 
 
80 
 
Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., 
Milne, R. L. ..... Garcia-Closas, M. (2011) Associations of breast 
cancer risk factors with tumor subtypes: a pooled analysis from the 
Breast Cancer Association Consortium studies. J Natl Cancer 
Inst, 103, 250-263. 
Young, J., Bulun, S. E., Agarwal, V., Couzinet, B., Mendelson, C. R., Simpson, 
E. R., Schaison, G. (1996). Aromatase expression in a feminizing 
adrenocortical tumor. J Clin Endocrinol Metab, 81 (9), 3173-3176.  
Yue, W., Zhou, D., Chen, S., Brodie, A. (1994). A new nude mouse model for 
postmenopausal breast cancer using MCF-7 cells transfected with the 
human aromatase gene. Cancer Research, 54, 5092–5095.  
Yue, W., Wang, J. P., Hamilton, C. J., Demers, L. M., Santen, R. J. (1998). In 
situ aromatization enhances breast tumor estradiol levels and cellular 
proliferation. Cancer Res, 58 (5), 927-932. 
Zharikova, O. L., Deshmukh, S. V., Nanovskaya, T. N., Hankins, G. D., Ahmed, 
M. S. (2006). The effect of methadone and buprenorphine on human 
placental aromatase. Biochem Pharmacol 71 (8), 1255-1264.  
Zhou, C., Zhou, D., Esteban, J., Murai, J., Siiteri, P. K., Wilczynski, S., Chen, S. 
(1996). Aromatase gene expression and its exon I usage in human 
breast tumors. Detection of aromatase messenger RNA by reverse 
transcription-polymerase chain reaction. Journal of Steroid 
Biochemistry and Molecular Biology, 59, 163–171.  
Zhou, J., Gurates, B., Yang, S., Sebastian, S., Bulun, S. E. (2001). Malignant 
breast epithelial cells stimulate aromatase expression via promoter II 
in human adipose fibroblasts: an epithelial-stromal interaction in 
breast tumors mediated by C/EBPbeta. Cancer Research, 61, 2328–
2334.  
Zhu B. T., Conney, A. H. (1998). Functional role of estrogen metabolism in target 
cells: review and perspectives. Carcinogenesis 19, 1–27. 
  
81 
 
CURRICULUM VITAE 
 
 
 
 
Name Surname : Mete Bora Tüzüner   
Place and Date of Birth : Balıkesir, 1984  
E-Mail : mboratuzuner@gmail.com 
 
EDUCATION :   
• B.Sc.   : 2006, Ege University, Faculty of Science,  
  Biochemistry 
• M.Sc.    : 2008, İstanbul University, Heatlh Sciences Inst.,  
     Molecular Medicine 
PROFESSIONAL EXPERIENCE AND REWARDS:  
• 2016-        , Dia Pro Medical Devices Co., R&D Director 
• 2013-2016, Ekinler Industry Co., Project Manager  
• 2013-2014 , Zivak Technologies, R&D Engineer 
• 2011-2012, Institute of Chemical Engineering, Vienna University of Technology, 
Research Associate 
• 2010-2011, Unit of Clinical Microbiology, Regional Reference Centre for 
Microbiological Emergencies (CRREM), St Orsola-Malpighi University 
Hospital, Research Associate 
• 2009-2010, Acıbadem Labmed, Molecular Microbiology Department, Laboratory 
Operator 
• 2007-2008, Infectious Diseases and Clinical Epidemiology Department  Marmara 
University, School of Medicine, Research Associate 
 
 
 
82 
 
PUBLICATIONS, PRESENTATIONS AND PATENTS ON THE THESIS: 
• Tuzuner BM, Ozturk T, Eronat AP, Turna H, Calay Z, Ilvan S, Seyhan FM, 
Kisakesen HI, Bermek H, Yılmaz-Aydoğan H, Oztürk O. Evaluation of Local 
CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in 
Postmenopausal Invasive Ductal Breast Cancer Cases. Biochem Genet (2016) 
54: 784. 
• Ozturk T, Kucukhuseyin O, Eronat AP, Tuzuner BM, Daglar-Aday A, Saygili 
N, Kisakesen HI, Seyhan MF, Velidedeoğlu M, Yılmaz-Aydoğan H, Ozturk O, 
İsbir T. Preliminary study: Prominent miRNAs of breast malignant tissues 
compared to normal tissues in Turkish breast cancer patients. Anticancer Res. 
2015 35(10):5425-32.  
•  Tüzüner BM, Oztürk T, Kisakesen HI, Ilvan S, Zerrin C, Oztürk O, Isbir T. 
CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative 
effects on breast cancer susceptibility. In Vivo. 2010; 24(1):71-4. 
• Öztürk T, Küçükhüseyin Ö, Tüzüner BM, Dağlar A, Saygılı N, Seyhan, İlvan Ş, 
Calay Z, Öztürk O. Alterations of some breast cancer related miRNA expression 
levels in invasive ductal cases: A retrospective study. The EMBO Meeting 2013, 
Amsterdam, NL  September 21-24, 2013.(poster presentation)    
• Tuzuner MB, Ozturk T, Calay Z, et al .: The relationship between estrogen 
metabolism genes CYP 17, CYP 19 and breast cancer. IUBMB LIFE 61(3): 366-
366 March 2009. (poster presentation)  
OTHER PUBLICATIONS, PRESENTATIONS AND PATENTS: 
• Karakoc C, Tuzuner BM, Ergonul MO, Pierro A, Fonzi E, Sambri V. West Nile 
Virus Infection in Mesopotomia region, Syria border of Turkey. Vector Borne 
Zoonotic Dis. 2013 Oct;13(10):739-43.  
• Ozbek YK, Oztürk T, Tüzüner BM, Calay Z, Ilvan S, Seyhan FM, Kisakesen 
HI, Oztürk O, Isbir T. Combined effect of CYP1B1 codon 432 polymorphism 
and N-acetyltransferase 2 slow acetylator phenotypes in relation to breast cancer 
in the Turkish population. Anticancer Res. 2010; 30(7):2885-9.  
• Tüzüner BM. Current Discussions About Genetically Modified Organisms. 
Turkish Family Physician. 2010; 1(2):1-7  
• O, Kağnici OF, Oztürk T, Durak H, Tüzüner BM, Kisakesen HI, Cakalir C, 
Isbir T. 192R allele of paraoxanase 1 (PON1) gene as a new marker for 
susceptibility to bladder cancer.  Anticancer Res. 2009; 29(10):4041-6. 
• M.F. Seyhan, O. Kurt, L.M. Yurdum, O. Kucukhuseyin, A.P. Eronat, O.T. 
Kahraman, M.B. Tuzuner, O. Ozturk. Investigation of CYP1A2*F and 
CYP1A2*D gene polymorphims in Turkish breast cancer patients. The EMBO 
Meeting 2013, Amsterdam, NL  September 21-24, 2013.(poster presentation)  
• Tüzüner BM, Timirci-Kahraman O, Saygılı N, Kısakesen HI, Yılmaz E, 
Yılmaz-Aydoğan H, Bilgiç S, Öztürk T, Seyhan MF, Eronat AP, Öztürk O. The 
effect of Apıs Mellıfera’s propolıs on cell cycle pathway ın MCF7 breast cancer 
cell lıne. Miami 2013 Winter Symposium – The Molecular Basis of Metabolism 
and Nutrition. Miami, FL, USA February 10-13, 2013.(poster presentation)  
83 
 
• Timirci-Kahraman O, Saygılı N, Kısakesen HI, Yılmaz E, Yılmaz-Aydoğan H, 
Bilgiç S, Öztürk T, Seyhan MF, Eronat AP, Tüzüner BM, Öztürk O. The effects 
of propolis with different geographic origin on whole genome expression profile 
of MCF7 breast cancer cells. 10th National Medical Genetics Congress. 19-23 
December 2012, Bursa. (oral presentation)  
• Saygılı N, Timirci-Kahraman O, Kısakesen HI, Yılmaz E, Yılmaz-Aydoğan H, 
Bilgiç S, Öztürk T, Seyhan MF, Eronat AP, Tüzüner BM, Öztürk O. The effects 
of propolis with different geographic origin on miRNA expression profile of 
MCF7 breast cancer cells. 4th Multidsipliner Cancer Research Congress. 13-16 
December 2012, Bursa. (oral presentation)  
• Ozbek YK, Ozturk T, Tuzuner MB, et al.: Investigation of gene polymorphisms 
of CYP1B1 and NAT2 detoxification enzymes in patients with breast cancer in 
Turkish population. IUBMB LIFE 61(3): 366-366, March 2009. (poster 
presentation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
 
 
 
 
